therapeutic_id,name,url,synonyms,fda_statuses,companies,target_types,therapy_types,approved_for,source_search_ids
aab-003,AAB-003,https://www.alzforum.org/therapeutics/aab-003,PF-05236812,Alzheimer's Disease (Discontinued),"Janssen, Pfizer",Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
aadvac1,AADvac1,https://www.alzforum.org/therapeutics/aadvac1,Axon peptide 108 conjugated to KLH,"Alzheimer's Disease (Phase 2), Progressive Nonfluent Aphasia (Phase 1)",Axon Neuroscience SE,Tau,Immunotherapy (active),,?fda_statuses[]=181&target_types[]=177 | ?fda_statuses[]=182&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=161 | ?fda_statuses[]=182&therapy_types[]=161 | ?therapy_types[]=161
aav-gad,AAV-GAD,https://www.alzforum.org/therapeutics/aav-gad,"AAV-GAD2, NLX-P101",Parkinson's Disease (Phase 2),"Hologen Limited, MeiraGTx Limited",Other Neurotransmitters,DNA/RNA-based,,?fda_statuses[]=182&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=164 | ?therapy_types[]=164
aav2-bdnf,AAV2-BDNF,https://www.alzforum.org/therapeutics/aav2-bdnf,,"MCI due to AD (Phase 1), Alzheimer's Disease (Phase 1)",,Other,DNA/RNA-based,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=164 | ?therapy_types[]=164
abbv-1088,ABBV-1088,https://www.alzforum.org/therapeutics/abbv-1088,,Parkinson's Disease (Phase 1),AbbVie,Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
abbv-552,ABBV-552,https://www.alzforum.org/therapeutics/abbv-552,,Alzheimer's Disease (Phase 1),AbbVie,Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
abbv-916,ABBV-916,https://www.alzforum.org/therapeutics/abbv-916,N3pG-Abeta mAb,Alzheimer's Disease (Discontinued),AbbVie,Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
abt-089,ABT-089,https://www.alzforum.org/therapeutics/abt-089,,Alzheimer's Disease (Discontinued),Abbott Laboratories,Cholinergic System,Small Molecule,,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
abt-288,ABT-288,https://www.alzforum.org/therapeutics/abt-288,,Alzheimer's Disease (Discontinued),AbbVie,"Cholinergic System, Other Neurotransmitters",Small Molecule,,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
abt-384,ABT-384,https://www.alzforum.org/therapeutics/abt-384,,Alzheimer's Disease (Discontinued),AbbVie,Other,Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
abt-418,ABT 418,https://www.alzforum.org/therapeutics/abt-418,,Alzheimer's Disease (Discontinued),,Cholinergic System,Small Molecule,None,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
abt-957,ABT-957,https://www.alzforum.org/therapeutics/abt-957,Alicapistat,Alzheimer's Disease (Discontinued),AbbVie,Other,Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
abvac40,ABvac40,https://www.alzforum.org/therapeutics/abvac40,,Alzheimer's Disease (Phase 2),Araclon Biotech,Amyloid-Related,Immunotherapy (active),,?fda_statuses[]=182&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=182&therapy_types[]=161 | ?therapy_types[]=161
acd856,ACD856,https://www.alzforum.org/therapeutics/acd856,,Alzheimer's Disease (Phase 1),AlzeCure Pharma AB,Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
acetyl-l-carnitine-hci,Acetyl-l-carnitine HCI,https://www.alzforum.org/therapeutics/acetyl-l-carnitine-hci,ALCAR,Alzheimer's Disease (Discontinued),Sigma-Tau Pharmaceuticals,Other,"Supplement, Dietary",,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=163 | ?therapy_types[]=163
aci-24060,ACI-24.060,https://www.alzforum.org/therapeutics/aci-24060,"ACI-24, Pal1-15 acetate salt","Alzheimer's Disease (Phase 2), Down's Syndrome (Phase 2)","AC Immune SA, Takeda Pharmaceutical Company",Amyloid-Related,Immunotherapy (active),,?fda_statuses[]=182&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=182&therapy_types[]=161 | ?therapy_types[]=161
aci-3024,ACI-3024,https://www.alzforum.org/therapeutics/aci-3024,Tau MorphomerTM,"Alzheimer's Disease (Inactive), Other Tauopathy (Phase 0)",AC Immune SA,Tau,Small Molecule,,?fda_statuses[]=190&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
aci-7104056,ACI-7104.056,https://www.alzforum.org/therapeutics/aci-7104056,"ACI-7104, Affitope PD01A, PD03A","Parkinson's Disease (Phase 2), Multiple System Atrophy (Phase 1)","AC Immune SA, AFFiRiS AG",alpha-synuclein,Immunotherapy (active),,?fda_statuses[]=181&therapy_types[]=161 | ?fda_statuses[]=182&therapy_types[]=161 | ?therapy_types[]=161
acitretin,Acitretin,https://www.alzforum.org/therapeutics/acitretin,"Soriatane , Neotigason, RO 101670",Alzheimer's Disease (Phase 2),"Actavis, Allergan plc",Amyloid-Related,Small Molecule,Psoriasis in US,?fda_statuses[]=182&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
acp-204,ACP-204,https://www.alzforum.org/therapeutics/acp-204,,Alzheimer's Disease (Phase 2/3),Acadia Pharmaceuticals,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=931&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=931&therapy_types[]=166 | ?therapy_types[]=166
adel-y01,ADEL-Y01,https://www.alzforum.org/therapeutics/adel-y01,,Alzheimer's Disease (Phase 1),"ADEL, Inc., Oscotec Inc.",Tau,Immunotherapy (passive),,?fda_statuses[]=181&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=162 | ?therapy_types[]=162
aduhelm,Aduhelm,https://www.alzforum.org/therapeutics/aduhelm,"Aducanumab, BIIB037",Alzheimer's Disease (Approved),"Biogen, Neurimmune",Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=184&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=184&therapy_types[]=162 | ?therapy_types[]=162
af-102b,AF 102B,https://www.alzforum.org/therapeutics/af-102b,"cevimeline HCL, Evoxac™",Alzheimer's Disease (Discontinued),"SnowBrand Pharmaceuticals, Inc.",Cholinergic System,Small Molecule,Treatment of dry mouth in Sjogren's syndrome.,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
affitope-ad02,Affitope AD02,https://www.alzforum.org/therapeutics/affitope-ad02,,Alzheimer's Disease (Discontinued),AFFiRiS AG,Amyloid-Related,Immunotherapy (active),,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=161 | ?therapy_types[]=161
agb101,AGB101,https://www.alzforum.org/therapeutics/agb101,levetiracetam,MCI-AD (Phase 2/3),"AgeneBio, Inc.",Amyloid-Related,Small Molecule,,?fda_statuses[]=931&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=931&therapy_types[]=166 | ?therapy_types[]=166
ait-101,AIT-101,https://www.alzforum.org/therapeutics/ait-101,"Apilimod, apilimod dimesylate, STA-5326, LAM-002A",Amyotrophic Lateral Sclerosis (Phase 2),OrphAI Therapeutics,Other,Small Molecule,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
akst4290,AKST4290,https://www.alzforum.org/therapeutics/akst4290,"ALK4290, lazucirnon",Parkinson's Disease (Phase 2),"Alkahest, Inc.",Inflammation,Small Molecule,,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
al002,AL002,https://www.alzforum.org/therapeutics/al002,,Alzheimer's Disease (Discontinued),"AbbVie, Alector",Inflammation,Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
al003,AL003,https://www.alzforum.org/therapeutics/al003,,Alzheimer's Disease (Discontinued),"AbbVie, Alector",Inflammation,Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
al044,AL044,https://www.alzforum.org/therapeutics/al044,,Alzheimer's Disease (Phase 1),Alector,Inflammation,Immunotherapy (passive),,?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&therapy_types[]=162 | ?therapy_types[]=162
al101,AL101,https://www.alzforum.org/therapeutics/al101,GSK-4527226,Alzheimer's Disease (Phase 2),"Alector, GlaxoSmithKline (GSK)",Other,Immunotherapy (passive),,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=162 | ?therapy_types[]=162
alia-1758,ALIA-1758,https://www.alzforum.org/therapeutics/alia-1758,,Alzheimer's Disease (Phase 1),"AbbVie, Aliada Therapeutics",Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=181&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&therapy_types[]=162 | ?therapy_types[]=162
allopregnanolone,Allopregnanolone,https://www.alzforum.org/therapeutics/allopregnanolone,"brexanolone, 3α-hydroxy-5α-pregnan-20-one, 3α,5α-tetrahydroprogesterone","Alzheimer's Disease (Phase 2), Parkinson's Disease (Phase 1)",,"Other Neurotransmitters, Other",Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&target_types[]=176 | ?fda_statuses[]=182&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=181&therapy_types[]=166 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
alpha-tocopherol,Alpha-Tocopherol,https://www.alzforum.org/therapeutics/alpha-tocopherol,Vitamin E,Alzheimer's Disease (Phase 3),,Other,"Supplement, Dietary",,?fda_statuses[]=183&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=183&therapy_types[]=163 | ?therapy_types[]=163
alx-001,ALX-001,https://www.alzforum.org/therapeutics/alx-001,BMS-984923,Alzheimer's Disease (Phase 1),"Allyx Therapeutics, Inc.","Amyloid-Related, Other Neurotransmitters",Small Molecule,,?fda_statuses[]=181&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
alz-101,ALZ-101,https://www.alzforum.org/therapeutics/alz-101,,Alzheimer's Disease (Phase 1),Alzinova AB,Amyloid-Related,Immunotherapy (active),,?fda_statuses[]=181&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&therapy_types[]=161 | ?therapy_types[]=161
alz-801,ALZ-801,https://www.alzforum.org/therapeutics/alz-801,"valiltramiprosate, NRM-8499, homotaurine prodrug, 3-APS",Alzheimer's Disease (Phase 3),Alzheon Inc.,Amyloid-Related,Small Molecule,,?fda_statuses[]=183&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
alzhemedtm,Alzhemed™,https://www.alzforum.org/therapeutics/alzhemedtm,"Vivimind™, Tramiprosate, NC-531, homotaurine, 3-APS",Alzheimer's Disease (Discontinued),"Neurochem, Inc.",Amyloid-Related,"Supplement, Dietary",None,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=163 | ?therapy_types[]=163
alzt-op1,ALZT-OP1,https://www.alzforum.org/therapeutics/alzt-op1,"Cromolyn sodium, Intal, Ibuprofen",Alzheimer's Disease (Phase 3),"AZTherapies, Inc.","Amyloid-Related, Inflammation","Combination, Small Molecule",,?fda_statuses[]=183&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=183&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=183&therapy_types[]=36536 | ?therapy_types[]=36536 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
ambroxol,Ambroxol,https://www.alzforum.org/therapeutics/ambroxol,"Ambrosan, Mucosolvan","Parkinson's Disease (Phase 2), Parkinson's Disease Dementia (Phase 2), Dementia with Lewy Bodies (Phase 2)",,"alpha-synuclein, Other",Small Molecule,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
amilomotide,Amilomotide,https://www.alzforum.org/therapeutics/amilomotide,CAD106,Alzheimer's Disease (Inactive),Novartis Pharmaceuticals Corporation,Amyloid-Related,Immunotherapy (active),None,?fda_statuses[]=190&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=190&therapy_types[]=161 | ?therapy_types[]=161
an-1792,AN-1792,https://www.alzforum.org/therapeutics/an-1792,AIP 001,Alzheimer's Disease (Discontinued),"Janssen, Pfizer",Amyloid-Related,Immunotherapy (active),None,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=161 | ?therapy_types[]=161
anpd001,ANPD001,https://www.alzforum.org/therapeutics/anpd001,DANPC (dopaminergic neuron precursor cell),Parkinson's Disease (Phase 1),Aspen Neuroscience,Other Neurotransmitters,Other,,?fda_statuses[]=181&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=181&therapy_types[]=167 | ?therapy_types[]=167
anx005,ANX005,https://www.alzforum.org/therapeutics/anx005,,Amyotrophic Lateral Sclerosis (Phase 2),"Annexon, Inc.","Inflammation, Other",Immunotherapy (passive),,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=162 | ?therapy_types[]=162
apabetalone,Apabetalone,https://www.alzforum.org/therapeutics/apabetalone,"RVX208, RVX000222",MCI-VaD (Phase 3),Resverlogix Corporation,Other,Small Molecule,,?fda_statuses[]=183&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
apnmab005,APNmAb005,https://www.alzforum.org/therapeutics/apnmab005,RAA7,Alzheimer's Disease (Phase 1),Aprinoia Therapeutics,Tau,Immunotherapy (passive),,?fda_statuses[]=181&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=162 | ?therapy_types[]=162
aqneursa,AQNEURSA,https://www.alzforum.org/therapeutics/aqneursa,"N-acetyl-L-leucine, NALL, IB1001, levacetylleucine","Niemann-Pick Diseases (Approved), Ataxia (Phase 3), Lysosomal Storage Diseases, Nervous System (Phase 2)",IntraBio,"Inflammation, Other",Small Molecule,Neurological symptoms of Niemann-Pick Disease Type C,?fda_statuses[]=182&target_types[]=173 | ?fda_statuses[]=183&target_types[]=173 | ?fda_statuses[]=184&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&target_types[]=175 | ?fda_statuses[]=183&target_types[]=175 | ?fda_statuses[]=184&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=183&therapy_types[]=166 | ?fda_statuses[]=184&therapy_types[]=166 | ?therapy_types[]=166
aqw051,AQW051,https://www.alzforum.org/therapeutics/aqw051,Alpha-7 nicotinic acetylcholine receptor agonist,"Alzheimer's Disease (Inactive), Parkinson's Disease (Phase 2), Schizophrenia (Phase 2)",Novartis Pharmaceuticals Corporation,Cholinergic System,Small Molecule,,?fda_statuses[]=182&target_types[]=172 | ?fda_statuses[]=190&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
ar1001,AR1001,https://www.alzforum.org/therapeutics/ar1001,,Alzheimer's Disease (Phase 3),"Aribio Co., Ltd.",Other,Small Molecule,,?fda_statuses[]=183&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
arimoclomol,Arimoclomol,https://www.alzforum.org/therapeutics/arimoclomol,MiplyffaTM,"Niemann-Pick Diseases (Approved), Amyotrophic Lateral Sclerosis (Discontinued), Gaucher Disease (Discontinued)",Zevra Therapeutics,"Cholesterol, Other",Small Molecule,Niemann-Pick Disease Type C,?fda_statuses[]=184&target_types[]=171 | ?fda_statuses[]=189&target_types[]=171 | ?target_types[]=171 | ?fda_statuses[]=184&target_types[]=175 | ?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=184&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
aripiprazole,Aripiprazole,https://www.alzforum.org/therapeutics/aripiprazole,"Abilify, BMS-337039","Alzheimer's Disease (Phase 3), Schizophrenia (Approved)","Bristol-Myers Squibb, Otsuka Pharmaceutical Co., Ltd.",Other Neurotransmitters,Small Molecule,,?fda_statuses[]=183&target_types[]=176 | ?fda_statuses[]=184&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=183&therapy_types[]=166 | ?fda_statuses[]=184&therapy_types[]=166 | ?therapy_types[]=166
arv-102,ARV-102,https://www.alzforum.org/therapeutics/arv-102,,Parkinson's Disease (Phase 1),"Arvinas, Inc.",Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
asn51,ASN51,https://www.alzforum.org/therapeutics/asn51,ASN121151,Alzheimer's Disease (Inactive),Asceneuron SA,Tau,Small Molecule,,?fda_statuses[]=190&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
asn90,ASN90,https://www.alzforum.org/therapeutics/asn90,"ASN120290, ASN-561",Progressive Supranuclear Palsy (Phase 1),Asceneuron SA,Tau,Small Molecule,,?fda_statuses[]=181&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
atabecestat,Atabecestat,https://www.alzforum.org/therapeutics/atabecestat,"JNJ-54861911 , BACE inhibitor",Alzheimer's Disease (Discontinued),"Janssen, Shionogi Pharma",Amyloid-Related,Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
atb2005a,ATB2005A,https://www.alzforum.org/therapeutics/atb2005a,ATC161,"Alzheimer's Disease (Phase 1), Progressive Supranuclear Palsy (Phase 1)",Autotac Bio Inc.,Tau,Small Molecule,,?fda_statuses[]=181&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
atomoxetine,Atomoxetine,https://www.alzforum.org/therapeutics/atomoxetine,"ATX, Strattera","Alzheimer's Disease (Phase 2), Parkinson's Disease (Phase 1)",Eli Lilly & Co.,Other Neurotransmitters,Small Molecule,ADHD in US,?fda_statuses[]=181&target_types[]=176 | ?fda_statuses[]=182&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=181&therapy_types[]=166 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
atorvastatin,Atorvastatin,https://www.alzforum.org/therapeutics/atorvastatin,"Lipitor™ , Zarator®, Sortis®, Tahor®",Alzheimer's Disease (Inactive),Pfizer,Cholesterol,Small Molecule,Hypercholesterolaemia,?fda_statuses[]=190&target_types[]=171 | ?target_types[]=171 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
atuzaginstat,Atuzaginstat,https://www.alzforum.org/therapeutics/atuzaginstat,COR388,Alzheimer's Disease (Discontinued),"Cortexyme, Inc., Quince Therapeutics",Other,Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
autologous-adipose-derived-stem-cells,Autologous Adipose-derived Stem Cells,https://www.alzforum.org/therapeutics/autologous-adipose-derived-stem-cells,"RB-ADSC, CEREWiNT®, Astrostem",Alzheimer's Disease (Phase 1/2),"Regeneration Biomedical, Inc.",Other,Other,,?fda_statuses[]=33251&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=33251&therapy_types[]=167 | ?therapy_types[]=167
av-1959d,AV-1959D,https://www.alzforum.org/therapeutics/av-1959d,AV-1959,Alzheimer's Disease (Phase 1),,Amyloid-Related,Immunotherapy (active),,?fda_statuses[]=181&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&therapy_types[]=161 | ?therapy_types[]=161
av-1980ra,AV-1980R/A,https://www.alzforum.org/therapeutics/av-1980ra,AV-1980R,Alzheimer's Disease (Phase 1),,Tau,Immunotherapy (active),,?fda_statuses[]=181&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=161 | ?therapy_types[]=161
avagacestat,Avagacestat,https://www.alzforum.org/therapeutics/avagacestat,BMS-708163,Alzheimer's Disease (Discontinued),Bristol-Myers Squibb,Amyloid-Related,Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
avb-101,AVB-101,https://www.alzforum.org/therapeutics/avb-101,,Frontotemporal Dementia (Phase 1/2),AviadoBio,Other,DNA/RNA-based,,?fda_statuses[]=33251&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=33251&therapy_types[]=164 | ?therapy_types[]=164
avp-786,AVP-786,https://www.alzforum.org/therapeutics/avp-786,,"Alzheimer's Disease (Discontinued), Schizophrenia (Discontinued)","Avanir Pharmaceuticals, Concert Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd.",Other Neurotransmitters,"Combination, Small Molecule",,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=36536 | ?therapy_types[]=36536 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
avp-923,AVP-923,https://www.alzforum.org/therapeutics/avp-923,"Nuedexta, Zenvia","Alzheimer's Disease (Phase 4), Amyotrophic Lateral Sclerosis (Phase 3), Parkinson's Disease (Phase 3)","Avanir Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd.",Other Neurotransmitters,"Combination, Small Molecule",,?fda_statuses[]=183&target_types[]=176 | ?fda_statuses[]=851&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=183&therapy_types[]=36536 | ?fda_statuses[]=851&therapy_types[]=36536 | ?therapy_types[]=36536 | ?fda_statuses[]=183&therapy_types[]=166 | ?fda_statuses[]=851&therapy_types[]=166 | ?therapy_types[]=166
axs-05,AXS-05,https://www.alzforum.org/therapeutics/axs-05,"Dextromethorphan/bupropion, Auvelity",Alzheimer's Disease (Phase 2/3),"Axsome Therapeutics, Inc.",Other Neurotransmitters,"Combination, Small Molecule",Major depressive disorder,?fda_statuses[]=931&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=931&therapy_types[]=36536 | ?therapy_types[]=36536 | ?fda_statuses[]=931&therapy_types[]=166 | ?therapy_types[]=166
azd1446,AZD1446,https://www.alzforum.org/therapeutics/azd1446,TC-6683,Alzheimer's Disease (Discontinued),"AstraZeneca, Targacept",Cholinergic System,Small Molecule,None,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
azd3293,Lanabecestat,https://www.alzforum.org/therapeutics/azd3293,"AZD3293 , LY3314814, BACE inhibitor",Alzheimer's Disease (Discontinued),"AstraZeneca, Eli Lilly & Co.",Amyloid-Related,Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
azd3480,AZD3480,https://www.alzforum.org/therapeutics/azd3480,"ispronicline, TC-1734",Alzheimer's Disease (Inactive),"AstraZeneca, Targacept",Cholinergic System,Small Molecule,,?fda_statuses[]=190&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
azeliragon,Azeliragon,https://www.alzforum.org/therapeutics/azeliragon,"PF-04494700, TTP488",Alzheimer's Disease (Discontinued),"Pfizer, TransTech Pharma, Inc., vTv Therapeutics LLC","Amyloid-Related, Inflammation",Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
bapineuzumab,Bapineuzumab,https://www.alzforum.org/therapeutics/bapineuzumab,AAB-001,Alzheimer's Disease (Discontinued),"Janssen, Pfizer",Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
baricitinib,Baricitinib,https://www.alzforum.org/therapeutics/baricitinib,"Olumiant®, NCB28050, LY3009104","Alzheimer's Disease (Phase 2), Amyotrophic Lateral Sclerosis (Phase 1)",Eli Lilly & Co.,Inflammation,Small Molecule,"Rheumatoid arthritis, Eczema (Europe, Japan only)",?fda_statuses[]=181&target_types[]=173 | ?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&therapy_types[]=166 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
bemdaneprocel,Bemdaneprocel,https://www.alzforum.org/therapeutics/bemdaneprocel,"BRT-DA01, MSK-DA01",Parkinson's Disease (Phase 1),"Bayer, BlueRock Therapeutics","Other Neurotransmitters, Other",Other,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=181&therapy_types[]=167 | ?therapy_types[]=167
benfotiamine,Benfotiamine,https://www.alzforum.org/therapeutics/benfotiamine,"S-benzoylthiamine-O-monophosphate, Vitamin B1, Thiamine",Alzheimer's Disease (Phase 2),,"Inflammation, Other","Supplement, Dietary",,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=163 | ?therapy_types[]=163
bepranemab,Bepranemab,https://www.alzforum.org/therapeutics/bepranemab,"UCB0107, UCB 0107, Antibody D","Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 2)","Hoffmann-La Roche, UCB S.A.",Tau,Immunotherapy (passive),,?fda_statuses[]=181&target_types[]=177 | ?fda_statuses[]=182&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=162 | ?fda_statuses[]=182&therapy_types[]=162 | ?therapy_types[]=162
besipirdine-hcl,Besipirdine HCl,https://www.alzforum.org/therapeutics/besipirdine-hcl,HP 749,Alzheimer's Disease (Discontinued),"Aventis Pharmaceuticals, Inc. (was Hoechst)",Other Neurotransmitters,Small Molecule,,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
bexarotene,Bexarotene,https://www.alzforum.org/therapeutics/bexarotene,Targretin®,Alzheimer's Disease (Phase 2),"Ligand Pharmaceuticals, Inc., ReXceptor Inc.","Amyloid-Related, Unknown",Small Molecule,Cutaneous T-cell Lymphoma in US,?fda_statuses[]=182&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=182&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
bezisterim,Bezisterim,https://www.alzforum.org/therapeutics/bezisterim,"NE3107, HE3286","Alzheimer's Disease (Phase 3), Parkinson's Disease (Phase 1/2)",BioVie Pharma,"Inflammation, Other",Small Molecule,,?fda_statuses[]=33251&target_types[]=173 | ?fda_statuses[]=183&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=33251&target_types[]=175 | ?fda_statuses[]=183&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=33251&therapy_types[]=166 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
bi-1181181,BI 1181181,https://www.alzforum.org/therapeutics/bi-1181181,"VTP 37948, BACE inhibitor",Alzheimer's Disease (Discontinued),"Boehringer Ingelheim, Vitae Pharmaceuticals",Amyloid-Related,Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
bi-409306,BI 409306,https://www.alzforum.org/therapeutics/bi-409306,SUB 166499,"Alzheimer's Disease (Discontinued), Schizophrenia (Phase 2)",Boehringer Ingelheim,"Other Neurotransmitters, Other",Small Molecule,,?fda_statuses[]=182&target_types[]=175 | ?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&target_types[]=176 | ?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
bifidobacterium-breve-a1,Bifidobacterium breve A1,https://www.alzforum.org/therapeutics/bifidobacterium-breve-a1,"MCC1274, B. breve",Mild Cognitive Impairment (Phase 2),"Morinaga Milk Industry Co., Ltd",Other,"Supplement, Dietary",,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=163 | ?therapy_types[]=163
biib076,BIIB076,https://www.alzforum.org/therapeutics/biib076,"NI-105, 6C5 huIgG1/l",Alzheimer's Disease (Discontinued),"Biogen, Eisai Co., Ltd., Neurimmune",Tau,Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
biib078,BIIB078,https://www.alzforum.org/therapeutics/biib078,"BIIB-078, IONIS-C9Rx",Amyotrophic Lateral Sclerosis (Discontinued),"Biogen, IONIS Pharmaceuticals",Other,DNA/RNA-based,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=164 | ?therapy_types[]=164
biib080,BIIB080,https://www.alzforum.org/therapeutics/biib080,"IONIS-MAPTRx, ISIS 814907",Alzheimer's Disease (Phase 1),"Biogen, IONIS Pharmaceuticals",Tau,DNA/RNA-based,,?fda_statuses[]=181&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=164 | ?therapy_types[]=164
biib100,BIIB100,https://www.alzforum.org/therapeutics/biib100,KPT-350,Amyotrophic Lateral Sclerosis (Discontinued),Biogen,"Inflammation, Other",Small Molecule,,?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
biib105,BIIB105,https://www.alzforum.org/therapeutics/biib105,ION541,Amyotrophic Lateral Sclerosis (Discontinued),"Biogen, IONIS Pharmaceuticals",Other,DNA/RNA-based,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=164 | ?therapy_types[]=164
biib113,BIIB113,https://www.alzforum.org/therapeutics/biib113,,Alzheimer's Disease (Discontinued),Biogen,Tau,Small Molecule,,?fda_statuses[]=189&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
biib118,BIIB118,https://www.alzforum.org/therapeutics/biib118,PF-05251749,"Alzheimer's Disease (Phase 1), Parkinson's Disease (Phase 1)",Biogen,Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
blarcamesine,Blarcamesine,https://www.alzforum.org/therapeutics/blarcamesine,Anavex 2-73,"Alzheimer's Disease (Phase 2/3), Parkinson's Disease Dementia (Phase 2), Parkinson's Disease (Phase 1)",Anavex Life Science Corp.,Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?fda_statuses[]=182&target_types[]=175 | ?fda_statuses[]=931&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=931&therapy_types[]=166 | ?therapy_types[]=166
bms-986446,BMS-986446,https://www.alzforum.org/therapeutics/bms-986446,PRX005,Alzheimer's Disease (Phase 2),"Bristol-Myers Squibb, Prothena",Tau,Immunotherapy (passive),,?fda_statuses[]=182&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=182&therapy_types[]=162 | ?therapy_types[]=162
bosutinib,Bosutinib,https://www.alzforum.org/therapeutics/bosutinib,"BOSULIF®, PF-5208763, SKI-606","Alzheimer's Disease (Phase 2), Dementia with Lewy Bodies (Phase 2)",Pfizer,Other,Small Molecule,Chronic myeloid leukemia,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
bpn14770,BPN14770,https://www.alzforum.org/therapeutics/bpn14770,,Alzheimer's Disease (Phase 2),"Shionogi Pharma, Tetra Therapeutics","Cholinergic System, Other",Small Molecule,,?fda_statuses[]=182&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
brexpiprazole,Brexpiprazole,https://www.alzforum.org/therapeutics/brexpiprazole,"Rexulti, OPC 34712","Alzheimer's Disease (Approved), Schizophrenia (Approved)","Lundbeck, Otsuka Pharmaceutical Co., Ltd.",Other Neurotransmitters,Small Molecule,,?fda_statuses[]=184&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=184&therapy_types[]=166 | ?therapy_types[]=166
bryostatin-1,Bryostatin 1,https://www.alzforum.org/therapeutics/bryostatin-1,,Alzheimer's Disease (Phase 2),"Synaptogenix, Inc.",Other,Other,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=167 | ?therapy_types[]=167
bt-267,BT-267,https://www.alzforum.org/therapeutics/bt-267,BT-0267,Parkinson's Disease (Phase 1),Brenig Therapeutics,Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
buntanetap,Buntanetap,https://www.alzforum.org/therapeutics/buntanetap,"Posiphen, ANVS-401, Posiphen tartrate","Alzheimer's Disease (Phase 2/3), Parkinson's Disease (Phase 3)",Annovis Bio,"Amyloid-Related, alpha-synuclein",Small Molecule,,?fda_statuses[]=931&target_types[]=170 | ?fda_statuses[]=183&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=931&therapy_types[]=166 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
bxcl501,BXCL501,https://www.alzforum.org/therapeutics/bxcl501,"Dexmedetomidine sublingual film, IGALMI™",Alzheimer's Disease (Phase 3),"BioXcel Therapeutics, Inc.",Other,Small Molecule,Acute Agitation in Schizophrenia and Bipolar Disorder,?fda_statuses[]=183&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
candesartan,Candesartan,https://www.alzforum.org/therapeutics/candesartan,"Atacand, Candesartan cilexetil","Mild Cognitive Impairment (Phase 2), Alzheimer's Disease (Phase 2)","AstraZeneca, Takeda Pharmaceutical Company",Other,Small Molecule,"Hypertension, congestive heart failure",?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
cannabidiol,Cannabidiol,https://www.alzforum.org/therapeutics/cannabidiol,"CBD, Epidiolex",Alzheimer's Disease (Phase 2),,Other Neurotransmitters,Small Molecule,"Seizures in Dravet syndrome, Lennox-Gastaut syndrome or tuberous sclerosis complex",?fda_statuses[]=182&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
carvedilol,Carvedilol,https://www.alzforum.org/therapeutics/carvedilol,"Coreg, Artist , Aucardic, Dilatrend, Kredex",Alzheimer's Disease (Phase 4),Procter & Gamble,Unknown,Small Molecule,"Hypertension, heart failure, angina pectoris",?fda_statuses[]=851&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=851&therapy_types[]=166 | ?therapy_types[]=166
cdnf,CDNF,https://www.alzforum.org/therapeutics/cdnf,cerebral dopamine neurotrophic factor,Parkinson's Disease (Phase 1/2),"Herantis Pharma Plc, Renishaw plc.",Other,"Procedural Intervention, Other",,?fda_statuses[]=33251&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=33251&therapy_types[]=167 | ?therapy_types[]=167 | ?fda_statuses[]=33251&therapy_types[]=165 | ?therapy_types[]=165
celecoxib,Celecoxib,https://www.alzforum.org/therapeutics/celecoxib,Celebrex,Alzheimer's Disease (Discontinued),Pfizer,Inflammation,Small Molecule,"Pain, Arthritis",?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
ceperognastat,Ceperognastat,https://www.alzforum.org/therapeutics/ceperognastat,LY3372689,Alzheimer's Disease (Discontinued),Eli Lilly & Co.,Tau,Small Molecule,,?fda_statuses[]=189&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
cere-110,CERE-110,https://www.alzforum.org/therapeutics/cere-110,Nerve Growth Factor gene therapy,Alzheimer's Disease (Discontinued),"Sangamo BioSciences, Inc.",Other,DNA/RNA-based,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=164 | ?therapy_types[]=164
cerebrolysin,Cerebrolysin,https://www.alzforum.org/therapeutics/cerebrolysin,,Alzheimer's Disease (Phase 2),Ebewe Pharmaceutical,Other,Other,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=167 | ?therapy_types[]=167
chf-5074,CHF 5074,https://www.alzforum.org/therapeutics/chf-5074,,"Mild Cognitive Impairment (Phase 2), Alzheimer's Disease (Inactive)","CereSpir™ Incorporated, Chiesi Pharmaceuticals Inc.","Amyloid-Related, Inflammation, Other",Small Molecule,,?fda_statuses[]=182&target_types[]=170 | ?fda_statuses[]=190&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=182&target_types[]=173 | ?fda_statuses[]=190&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&target_types[]=175 | ?fda_statuses[]=190&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
cinpanemab,Cinpanemab,https://www.alzforum.org/therapeutics/cinpanemab,"BIIB054, NI-202",Parkinson's Disease (Discontinued),"Biogen, Neurimmune",alpha-synuclein,Immunotherapy (passive),,?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
circadin,Circadin,https://www.alzforum.org/therapeutics/circadin,,Alzheimer's Disease (Phase 2),Neurim Pharmaceuticals Ltd.,Other,Small Molecule,Insomnia,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
citalopram,Citalopram,https://www.alzforum.org/therapeutics/citalopram,"escitalopram, Celexa, Lexapro , Cipralex","Alzheimer's Disease (Phase 3), Preclinical Alzheimer's Disease (Inactive)",,Other Neurotransmitters,Small Molecule,"Depression, generalized anxiety disorder",?fda_statuses[]=183&target_types[]=176 | ?fda_statuses[]=190&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=183&therapy_types[]=166 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
clioquinol,Clioquinol,https://www.alzforum.org/therapeutics/clioquinol,"iodochlorhydroxyquin, PBT-1",Alzheimer's Disease (Discontinued),Prana Biotechnology Limited,"Amyloid-Related, Metals",Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&target_types[]=174 | ?target_types[]=174 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
cnm-au8,CNM-Au8,https://www.alzforum.org/therapeutics/cnm-au8,Gold nanocrystals,"Parkinson's Disease (Phase 2), Amyotrophic Lateral Sclerosis (Phase 2/3)","Clene Nanomedicine, Inc.","Metals, Other",Other,,?fda_statuses[]=182&target_types[]=174 | ?fda_statuses[]=931&target_types[]=174 | ?target_types[]=174 | ?fda_statuses[]=182&target_types[]=175 | ?fda_statuses[]=931&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=167 | ?fda_statuses[]=931&therapy_types[]=167 | ?therapy_types[]=167
cocoa-flavanols,Cocoa Flavanols,https://www.alzforum.org/therapeutics/cocoa-flavanols,,Mild Cognitive Impairment (Not Regulated),,"Inflammation, Other","Supplement, Dietary",,?fda_statuses[]=33161&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=33161&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=33161&therapy_types[]=163 | ?therapy_types[]=163
cognishunt%E2%84%A2,COGNIShunt™,https://www.alzforum.org/therapeutics/cognishunt%E2%84%A2,,Alzheimer's Disease (Inactive),,Other,Procedural Intervention,None,?fda_statuses[]=190&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=190&therapy_types[]=165 | ?therapy_types[]=165
continuous-positive-airway-pressure,Continuous Positive Airway Pressure,https://www.alzforum.org/therapeutics/continuous-positive-airway-pressure,CPAP,Alzheimer's Disease (Phase 3),,Unknown,Procedural Intervention,Sleep Apnea in US,?fda_statuses[]=183&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=183&therapy_types[]=165 | ?therapy_types[]=165
coya-302,COYA 302,https://www.alzforum.org/therapeutics/coya-302,IL2 plus Abatacept,"Amyotrophic Lateral Sclerosis (Phase 1), Frontotemporal Dementia (Phase 1)",Coya Therapeutics,Inflammation,"Combination, Other",,?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&therapy_types[]=36536 | ?therapy_types[]=36536 | ?fda_statuses[]=181&therapy_types[]=167 | ?therapy_types[]=167
cpg-1018r,CpG 1018®,https://www.alzforum.org/therapeutics/cpg-1018r,"CpG oligodeoxynucleotides, CpG ODN",Alzheimer's Disease (Phase 1),Dynavax Technologies,"Amyloid-Related, Inflammation","Immunotherapy (active), DNA/RNA-based",,?fda_statuses[]=181&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&therapy_types[]=164 | ?therapy_types[]=164 | ?fda_statuses[]=181&therapy_types[]=161 | ?therapy_types[]=161
crenezumab,Crenezumab,https://www.alzforum.org/therapeutics/crenezumab,"MABT5102A , RG7412",Alzheimer's Disease (Discontinued),"AC Immune SA, Genentech, Hoffmann-La Roche",Amyloid-Related,Immunotherapy (passive),None,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
cs6253,CS6253,https://www.alzforum.org/therapeutics/cs6253,"Cogpep™, CS-6253",Alzheimer's Disease (Phase 1),"Artery Therapeutics, Inc.","Amyloid-Related, Cholesterol",Small Molecule,,?fda_statuses[]=181&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&target_types[]=171 | ?target_types[]=171 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
cst-103,CST-103,https://www.alzforum.org/therapeutics/cst-103,Clenbuterol,"Mild Cognitive Impairment (Phase 2), Parkinson's Disease (Phase 2), Amyotrophic Lateral Sclerosis (Phase 2)",,Other Neurotransmitters,Small Molecule,"Asthma, in countries outside the U.S.",?fda_statuses[]=182&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
cst-2032,CST-2032,https://www.alzforum.org/therapeutics/cst-2032,,"Mild Cognitive Impairment (Phase 2), Parkinson's Disease (Phase 2)","CuraSen Therapeutics, Inc.",Other Neurotransmitters,Small Molecule,,?fda_statuses[]=182&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
curcumin,Curcumin,https://www.alzforum.org/therapeutics/curcumin,"diferuloylmethane, Longvida™",Alzheimer's Disease (Phase 2),Verdure Sciences,"Other, Unknown","Supplement, Dietary",None,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=182&therapy_types[]=163 | ?therapy_types[]=163
cx516,CX516,https://www.alzforum.org/therapeutics/cx516,Ampalex,Alzheimer's Disease (Discontinued),"Cortex Pharmaceuticals, Inc.",Other Neurotransmitters,Small Molecule,None,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
cy6463,CY6463,https://www.alzforum.org/therapeutics/cy6463,IW-6463,Alzheimer's Disease (Phase 2),Cyclerion,Inflammation,Small Molecule,,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
dapagliflozin,Dapagliflozin,https://www.alzforum.org/therapeutics/dapagliflozin,"Farxiga, Forxiga, BMS 512148",Alzheimer's Disease (Phase 1/2),"AstraZeneca, Bristol-Myers Squibb",Other,Small Molecule,,?fda_statuses[]=33251&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=33251&therapy_types[]=166 | ?therapy_types[]=166
dapsone,Dapsone,https://www.alzforum.org/therapeutics/dapsone,"Avlosulfon, Diaminodiphenylsulfone, DDS",Alzheimer's Disease (Inactive),Immune Network Ltd.,Other,Small Molecule,"Leprosy, malaria, some bacterial skin infections",?fda_statuses[]=190&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
dasatinib-quercetin,Dasatinib + Quercetin,https://www.alzforum.org/therapeutics/dasatinib-quercetin,,Alzheimer's Disease (Phase 1/2),,"Tau, Other","Combination, Small Molecule, Supplement, Dietary",,?fda_statuses[]=33251&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=33251&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=33251&therapy_types[]=36536 | ?therapy_types[]=36536 | ?fda_statuses[]=33251&therapy_types[]=166 | ?therapy_types[]=166 | ?fda_statuses[]=33251&therapy_types[]=163 | ?therapy_types[]=163
davunetide,Davunetide,https://www.alzforum.org/therapeutics/davunetide,"NAP, AL-108","Mild Cognitive Impairment (Inactive), Progressive Supranuclear Palsy (Inactive), Schizophrenia (Inactive), Frontotemporal Dementia (Inactive), Autism Spectrum Disorder (Phase 3)","Allon Therapeutics Inc., Exonavis Therapeutics Ltd., Paladin Labs Inc.",Tau,Other,,?fda_statuses[]=183&target_types[]=177 | ?fda_statuses[]=190&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=183&therapy_types[]=167 | ?fda_statuses[]=190&therapy_types[]=167 | ?therapy_types[]=167
dayvigo,Dayvigo,https://www.alzforum.org/therapeutics/dayvigo,"Lemborexant, E2006",Alzheimer's Disease (Phase 2),"Eisai Co., Ltd.",Other,Small Molecule,Insomnia,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
deep-brain-stimulation-fornix,Deep Brain Stimulation-fornix,https://www.alzforum.org/therapeutics/deep-brain-stimulation-fornix,DBS-f,Alzheimer's Disease (Phase 3),Functional Neuromodulation Ltd,Unknown,Procedural Intervention,,?fda_statuses[]=183&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=183&therapy_types[]=165 | ?therapy_types[]=165
deep-brain-stimulation-nucleus-basalis-meynert,Deep Brain Stimulation-nucleus basalis of Meynert,https://www.alzforum.org/therapeutics/deep-brain-stimulation-nucleus-basalis-meynert,DBS-nbM,Alzheimer's Disease (Phase 2),,"Cholinergic System, Other",Procedural Intervention,,?fda_statuses[]=182&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=165 | ?therapy_types[]=165
deferiprone,Deferiprone,https://www.alzforum.org/therapeutics/deferiprone,Ferriprox,"Alzheimer's Disease (Phase 2), Parkinson's Disease (Phase 2/3), Amyotrophic Lateral Sclerosis (Phase 2/3)","Apotex Inc., Chiesi Pharmaceuticals Inc.",Metals,Small Molecule,Iron overload due to thalassemia syndromes,?fda_statuses[]=182&target_types[]=174 | ?fda_statuses[]=931&target_types[]=174 | ?target_types[]=174 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=931&therapy_types[]=166 | ?therapy_types[]=166
dexpramipexole,Dexpramipexole,https://www.alzforum.org/therapeutics/dexpramipexole,"R-pramipexole, RPPX, KNS-760704 , BIIB 050","Alzheimer's Disease (Phase 2), Amyotrophic Lateral Sclerosis (Discontinued)","Biogen, Knopp Biosciences LLC, Virginia Commonwealth University","Other Neurotransmitters, Other",Small Molecule,,?fda_statuses[]=182&target_types[]=175 | ?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&target_types[]=176 | ?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
dimebon,Dimebon,https://www.alzforum.org/therapeutics/dimebon,"Dimebolin, Latrepirdine, Pf-01913539","Alzheimer's Disease (Discontinued), Huntington's Disease (Discontinued)","Medivation, Inc.","Other Neurotransmitters, Unknown",Small Molecule,Anti-histamine use in Russia,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
dipraglurant,Dipraglurant,https://www.alzforum.org/therapeutics/dipraglurant,ADX48621,Parkinson's Disease (Discontinued),Addex Therapeutics,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
dnl151,DNL151,https://www.alzforum.org/therapeutics/dnl151,BIIB122,Parkinson's Disease (Phase 2),"Biogen, Denali Therapeutics Inc.","Inflammation, Other",Small Molecule,,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
dnl201,DNL201,https://www.alzforum.org/therapeutics/dnl201,,Parkinson's Disease (Inactive),"Biogen, Denali Therapeutics Inc.","Inflammation, Other",Small Molecule,,?fda_statuses[]=190&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=190&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
dnl343,DNL343,https://www.alzforum.org/therapeutics/dnl343,,Amyotrophic Lateral Sclerosis (Discontinued),Denali Therapeutics Inc.,Other,Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
dnl593,DNL593,https://www.alzforum.org/therapeutics/dnl593,"PTV:PGRN, TAK-594",Frontotemporal Dementia (Phase 1/2),"Denali Therapeutics Inc., Takeda Pharmaceutical Company",Other,Other,,?fda_statuses[]=33251&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=33251&therapy_types[]=167 | ?therapy_types[]=167
dnl747,DNL747,https://www.alzforum.org/therapeutics/dnl747,SAR443060,"Alzheimer's Disease (Inactive), Amyotrophic Lateral Sclerosis (Inactive)","Denali Therapeutics Inc., Sanofi",Inflammation,Small Molecule,,?fda_statuses[]=190&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
dnl788,DNL788,https://www.alzforum.org/therapeutics/dnl788,"SAR443820, oditrasertib",Amyotrophic Lateral Sclerosis (Discontinued),"Denali Therapeutics Inc., Sanofi",Inflammation,Small Molecule,,?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
dnl919,DNL919,https://www.alzforum.org/therapeutics/dnl919,"TAK-920, ATV:TREM2",Alzheimer's Disease (Discontinued),"Denali Therapeutics Inc., Takeda Pharmaceutical Company","Amyloid-Related, Inflammation",Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
docosahexaenoic-acid-dha,Docosahexaenoic acid (DHA),https://www.alzforum.org/therapeutics/docosahexaenoic-acid-dha,Omega-3 fatty acid,Alzheimer's Disease (Phase 4),"Martek Biosciences Corporation, NeuroBioPharm, Inc.",Other,"Supplement, Dietary",,?fda_statuses[]=851&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=851&therapy_types[]=163 | ?therapy_types[]=163
donepezil,Donepezil,https://www.alzforum.org/therapeutics/donepezil,"Aricept™, Donepezil hydrochloride, Eranz®, E 2020","Alzheimer's Disease (Approved), Dementia with Lewy Bodies (Inactive), Down's Syndrome (Inactive), Parkinson's Disease Dementia (Inactive)","Corium, Inc., Eisai Co., Ltd., Pfizer",Cholinergic System,Small Molecule,"Alzheimer's Disease, Dementia with Lewy Bodies (Japan)",?fda_statuses[]=184&target_types[]=172 | ?fda_statuses[]=190&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=184&therapy_types[]=166 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
dronabinol,Dronabinol,https://www.alzforum.org/therapeutics/dronabinol,"THC , Marinol, Syndros, delta-9-tetrahydrocannabinol, delta-9-THC",Alzheimer's Disease (Phase 2),"AbbVie, Others",Other Neurotransmitters,Small Molecule,Anorexia and weight loss in people with AIDS; Second-line treatment of nausea and vomiting due to chemotherapy,?fda_statuses[]=182&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
e2511,E2511,https://www.alzforum.org/therapeutics/e2511,,Alzheimer's Disease (Phase 1),"Eisai Co., Ltd.",Cholinergic System,Small Molecule,,?fda_statuses[]=181&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
edaravone,Edaravone,https://www.alzforum.org/therapeutics/edaravone,"MCI-186, Radicava®, Radicut®, MT-1186, FAB122",Amyotrophic Lateral Sclerosis (Phase 4),Mitsubishi Tanabe Pharma,Other,Small Molecule,Amyotrophic Lateral Sclerosis,?fda_statuses[]=851&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=851&therapy_types[]=166 | ?therapy_types[]=166
edicotinib,Edicotinib,https://www.alzforum.org/therapeutics/edicotinib,"JNJ-40346527, JNJ-527, PRV-6527",Alzheimer's Disease (Phase 1),Janssen,Inflammation,Small Molecule,,?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
edonerpic,Edonerpic,https://www.alzforum.org/therapeutics/edonerpic,"T-817 MA, T 817",Alzheimer's Disease (Discontinued),"Toyama Chemical Co., Ltd.","Other, Unknown",Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
efavirenz,Efavirenz,https://www.alzforum.org/therapeutics/efavirenz,Efavirenz,Alzheimer's Disease (Phase 1),,"Amyloid-Related, Tau, Cholesterol",Small Molecule,HIV infection,?fda_statuses[]=181&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&target_types[]=171 | ?target_types[]=171 | ?fda_statuses[]=181&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
eht-0202,EHT 0202,https://www.alzforum.org/therapeutics/eht-0202,Etazolate,Alzheimer's Disease (Phase 2),ExonHit Therapeutics,Other,Small Molecule,None,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
elenbecestat,Elenbecestat,https://www.alzforum.org/therapeutics/elenbecestat,"E2609, BACE inhibitor",Alzheimer's Disease (Discontinued),"Biogen, Eisai Co., Ltd.",Amyloid-Related,Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
elnd005,ELND005,https://www.alzforum.org/therapeutics/elnd005,"AZD-103, Scyllo-inositol, cyclohexane-1,2,3,4,5,6-hexol",Alzheimer's Disease (Inactive),"Elan Corporation, Opko Health, Speranza Therapeutics, Transition Therapeutics, Inc.",Amyloid-Related,Small Molecule,None,?fda_statuses[]=190&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
empagliflozin,Empagliflozin,https://www.alzforum.org/therapeutics/empagliflozin,"Jardiance, BI-10773",Alzheimer's Disease (Phase 1),"Boehringer Ingelheim, Eli Lilly & Co.",Other,Small Molecule,"Type 2 Diabetes, Cardiovascular disease",?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
emrusolmin,Emrusolmin,https://www.alzforum.org/therapeutics/emrusolmin,"Anle138b, TEV-56286","Parkinson's Disease (Phase 1/2), Multiple System Atrophy (Phase 2)","MODAG GmbH, Teva","Tau, alpha-synuclein, Other",Small Molecule,,?fda_statuses[]=33251&target_types[]=175 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=33251&target_types[]=177 | ?fda_statuses[]=182&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=33251&therapy_types[]=166 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
emtricitabine,Emtricitabine,https://www.alzforum.org/therapeutics/emtricitabine,,Alzheimer's Disease (Phase 1),"Gilead Sciences, Inc.",Inflammation,"Small Molecule, DNA/RNA-based","HIV infection, Hepatitis B infection",?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&therapy_types[]=164 | ?therapy_types[]=164 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
encenicline,Encenicline,https://www.alzforum.org/therapeutics/encenicline,"EVP-6124 , MT-4666, α7-nAChR agonist","Alzheimer's Disease (Discontinued), Schizophrenia (Discontinued)","FORUM Pharmaceuticals Inc., Mitsubishi Tanabe Pharma",Cholinergic System,Small Molecule,None,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
engensis-0,Engensis,https://www.alzforum.org/therapeutics/engensis-0,"VM202, pCK-HGF-X7, NL003, hepatocyte growth factor",Amyotrophic Lateral Sclerosis (Phase 2),Helixmith,Other,DNA/RNA-based,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=164 | ?therapy_types[]=164
epigallocatechin-gallate-egcg,Epigallocatechin Gallate (EGCG),https://www.alzforum.org/therapeutics/epigallocatechin-gallate-egcg,Sunphenon EGCg,"Alzheimer's Disease (Phase 2/3), Down's Syndrome (Phase 2), Multiple System Atrophy (Phase 3)",Taiyo International,"Amyloid-Related, Inflammation, Other","Supplement, Dietary",,?fda_statuses[]=182&target_types[]=170 | ?fda_statuses[]=931&target_types[]=170 | ?fda_statuses[]=183&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=182&target_types[]=173 | ?fda_statuses[]=931&target_types[]=173 | ?fda_statuses[]=183&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&target_types[]=175 | ?fda_statuses[]=931&target_types[]=175 | ?fda_statuses[]=183&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=163 | ?fda_statuses[]=931&therapy_types[]=163 | ?fda_statuses[]=183&therapy_types[]=163 | ?therapy_types[]=163
epothilone-d,Epothilone D,https://www.alzforum.org/therapeutics/epothilone-d,BMS-241027,Alzheimer's Disease (Discontinued),Bristol-Myers Squibb,Tau,Small Molecule,,?fda_statuses[]=189&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
eptastigmine,Eptastigmine,https://www.alzforum.org/therapeutics/eptastigmine,MF 201,Alzheimer's Disease (Discontinued),Mediolanum,Cholinergic System,Small Molecule,None,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
estrogen,Estrogen,https://www.alzforum.org/therapeutics/estrogen,Premarin™,Alzheimer's Disease (Discontinued),,Other,Other,Hormone Replacement Therapy,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=167 | ?therapy_types[]=167
etalanetug,Etalanetug,https://www.alzforum.org/therapeutics/etalanetug,E2814,Alzheimer's Disease (Phase 2/3),"Eisai Co., Ltd.",Tau,Immunotherapy (passive),,?fda_statuses[]=931&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=931&therapy_types[]=162 | ?therapy_types[]=162
etanercept,Etanercept,https://www.alzforum.org/therapeutics/etanercept,Enbrel™,Alzheimer's Disease (Phase 2),"Amgen, Inc., Pfizer",Inflammation,Immunotherapy (passive),"Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondilysis",?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&therapy_types[]=162 | ?therapy_types[]=162
evp-0962,EVP-0962,https://www.alzforum.org/therapeutics/evp-0962,EVP 0015962,"Alzheimer's Disease (Discontinued), Mild Cognitive Impairment (Discontinued)",FORUM Pharmaceuticals Inc.,Amyloid-Related,Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
exenatide,Exenatide,https://www.alzforum.org/therapeutics/exenatide,"Exendin-4, Byetta, Bydureon","Alzheimer's Disease (Inactive), Parkinson's Disease (Phase 3)","AstraZeneca, Eli Lilly & Co.",Other,Small Molecule,Diabetes mellitus in US,?fda_statuses[]=183&target_types[]=175 | ?fda_statuses[]=190&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=183&therapy_types[]=166 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
exidavnemab,Exidavnemab,https://www.alzforum.org/therapeutics/exidavnemab,"BAN0805, ABBV-0805","Parkinson's Disease (Phase 2), Multiple System Atrophy (Phase 2)","AbbVie, BioArctic AB",alpha-synuclein,Immunotherapy (passive),,?fda_statuses[]=182&therapy_types[]=162 | ?therapy_types[]=162
ezeprogind,Ezeprogind,https://www.alzforum.org/therapeutics/ezeprogind,"AZP2006 , AZP-2006",Progressive Supranuclear Palsy (Phase 2),AlzProtect,"Tau, Inflammation, Other",Small Molecule,,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
flurizan,Flurizan™,https://www.alzforum.org/therapeutics/flurizan,"tarenflurbil , r-flurbiprofen, MPC-7869",Alzheimer's Disease (Discontinued),Myriad Genetics & Laboratories,Amyloid-Related,Small Molecule,None,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
focused-ultrasound-blood-brain-barrier,Focused Ultrasound – Blood-Brain Barrier,https://www.alzforum.org/therapeutics/focused-ultrasound-blood-brain-barrier,"FUS-BBB, MRgFUS, MRI-Guided Focused Ultrasound, FUS+MB","Alzheimer's Disease (Phase 1), Amyotrophic Lateral Sclerosis (Phase 1), Mild Cognitive Impairment (Phase 1), Parkinson's Disease (Phase 1)",,"Amyloid-Related, Other",Procedural Intervention,,?fda_statuses[]=181&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=165 | ?therapy_types[]=165
foralumab,Foralumab,https://www.alzforum.org/therapeutics/foralumab,"TZLS-401, NI-0401, 28F11-AE","Alzheimer's Disease (Phase 2), Amyotrophic Lateral Sclerosis (Phase 2)",Tiziana Life Sciences,Inflammation,Immunotherapy (passive),,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&therapy_types[]=162 | ?therapy_types[]=162
fosgonimeton,Fosgonimeton,https://www.alzforum.org/therapeutics/fosgonimeton,"ATH-1017, NDX-1017","Alzheimer's Disease (Discontinued), Dementia with Lewy Bodies (Discontinued), Parkinson's Disease Dementia (Discontinued)",Athira Pharma,Other,Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
fosigotifator,Fosigotifator,https://www.alzforum.org/therapeutics/fosigotifator,"ABBV-CLS-7262, Fosigotifator sodium tromethamine",Amyotrophic Lateral Sclerosis (Discontinued),"AbbVie, Calico Life Sciences LLC.",Other,Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
frm-0334,FRM-0334,https://www.alzforum.org/therapeutics/frm-0334,EVP-0334,Frontotemporal Dementia (Discontinued),FORUM Pharmaceuticals Inc.,Other,Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
g-csf,G-CSF,https://www.alzforum.org/therapeutics/g-csf,Filgrastim,Alzheimer's Disease (Phase 2),,Other,Small Molecule,Neutropenia in US,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
galantamine,Galantamine,https://www.alzforum.org/therapeutics/galantamine,"Razadyne™, Reminyl™, Nivalin®",Alzheimer's Disease (Approved),"Janssen, Ortho-McNeil Pharmaceutical, Sanochemia Pharmazeutika, Shire, Takeda Pharmaceutical Company",Cholinergic System,Small Molecule,Mild to Moderate Alzheimer's disease,?fda_statuses[]=184&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=184&therapy_types[]=166 | ?therapy_types[]=166
gammagardr,Gammagard®,https://www.alzforum.org/therapeutics/gammagardr,"Intravenous Immunoglobulin, IVIg",Alzheimer's Disease (Discontinued),Baxter Healthcare,"Amyloid-Related, Inflammation",Immunotherapy (passive),Immunodeficiency conditions,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
gamunex,Gamunex,https://www.alzforum.org/therapeutics/gamunex,"Intravenous Immunoglobulin, Human Albumin Combined With Flebogamma",Alzheimer's Disease (Phase 2/3),Grifols Biologicals Inc.,"Amyloid-Related, Inflammation","Combination, Immunotherapy (passive)","Immunodeficiency, chronic inflammatory demyelinating neuropathy",?fda_statuses[]=931&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=931&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=931&therapy_types[]=36536 | ?therapy_types[]=36536 | ?fda_statuses[]=931&therapy_types[]=162 | ?therapy_types[]=162
gantenerumab,Gantenerumab,https://www.alzforum.org/therapeutics/gantenerumab,"RO4909832, RG1450, R1450",Alzheimer's Disease (Discontinued),"Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche",Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
gc021109,GC021109,https://www.alzforum.org/therapeutics/gc021109,,Alzheimer's Disease (Phase 1),GliaCure,Inflammation,Small Molecule,,?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
gemfibrozil,Gemfibrozil,https://www.alzforum.org/therapeutics/gemfibrozil,"Lopid, Jezil, Gen-Fibro",Alzheimer's Disease (Phase 1),,Cholesterol,Small Molecule,Hyperlipidemia,?fda_statuses[]=181&target_types[]=171 | ?target_types[]=171 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
gosuranemab,Gosuranemab,https://www.alzforum.org/therapeutics/gosuranemab,"BIIB092, BMS-986168, IPN007","Progressive Supranuclear Palsy (Discontinued), Alzheimer's Disease (Discontinued)","Biogen, Bristol-Myers Squibb",Tau,Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
grf6019,GRF6019,https://www.alzforum.org/therapeutics/grf6019,,Alzheimer's Disease (Phase 2),"Alkahest, Inc., Grifols Biologicals Inc.","Inflammation, Other, Unknown",Other,,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=182&therapy_types[]=167 | ?therapy_types[]=167
grf6021,GRF6021,https://www.alzforum.org/therapeutics/grf6021,AKST/GRF6021,Parkinson's Disease Dementia (Phase 2),"Alkahest, Inc., Grifols Biologicals Inc.","Inflammation, Other, Unknown",Other,,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=182&therapy_types[]=167 | ?therapy_types[]=167
gsk239512,GSK239512,https://www.alzforum.org/therapeutics/gsk239512,,Alzheimer's Disease (Discontinued),GlaxoSmithKline (GSK),"Cholinergic System, Other Neurotransmitters",Small Molecule,,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
gsk2647544,GSK2647544,https://www.alzforum.org/therapeutics/gsk2647544,GSK-2647544,Alzheimer's Disease (Phase 1),GlaxoSmithKline (GSK),Cholesterol,Small Molecule,,?fda_statuses[]=181&target_types[]=171 | ?target_types[]=171 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
gsk933776,GSK933776,https://www.alzforum.org/therapeutics/gsk933776,,Alzheimer's Disease (Inactive),GlaxoSmithKline (GSK),Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=190&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=190&therapy_types[]=162 | ?therapy_types[]=162
gt-02287,GT-02287,https://www.alzforum.org/therapeutics/gt-02287,,Parkinson's Disease (Phase 1),"Gain Therapeutics, Inc.","alpha-synuclein, Other",Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
guanfacine,Guanfacine,https://www.alzforum.org/therapeutics/guanfacine,"Intuniv, SPD503, Afken, Estulic, Tenex",Alzheimer's Disease (Phase 3),,Other Neurotransmitters,Small Molecule,"Attention-deficit hyperactivity disorder, hypertension",?fda_statuses[]=183&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
gv-971,GV-971,https://www.alzforum.org/therapeutics/gv-971,"sodium oligomannate, sodium oligo-mannurarate",Alzheimer's Disease (Inactive),Shanghai Green Valley Pharmaceuticals,"Amyloid-Related, Inflammation",Small Molecule,,?fda_statuses[]=190&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=190&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
gv1001,GV1001,https://www.alzforum.org/therapeutics/gv1001,"RIAVAXTM, Tertomotide",Alzheimer's Disease (Phase 3),GemVax & KAEL Bio,Other,Immunotherapy (active),Pancreatic cancer (Korea),?fda_statuses[]=183&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=183&therapy_types[]=161 | ?therapy_types[]=161
hf0220,HF0220,https://www.alzforum.org/therapeutics/hf0220,,Alzheimer's Disease (Discontinued),Newron,Inflammation,Small Molecule,,?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
hmtm,HMTM,https://www.alzforum.org/therapeutics/hmtm,"LMTM, LMTX, LMT-X, TRx0237, Tau aggregation inhibitor (TAI), Methylene Blue","Alzheimer's Disease (Phase 3), Frontotemporal Dementia (Phase 3)",TauRx Therapeutics Ltd,Tau,Small Molecule,Methylene Blue predates FDA. Used for treatment of malaria and methemoglobinemia.,?fda_statuses[]=183&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
htl0018318,HTL0018318,https://www.alzforum.org/therapeutics/htl0018318,,"Alzheimer's Disease (Inactive), Dementia with Lewy Bodies (Inactive)","Allergan plc, Sosei Heptares",Cholinergic System,Small Molecule,,?fda_statuses[]=190&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
huperzine,Huperzine A,https://www.alzforum.org/therapeutics/huperzine,"ZT-1, DEBIO 9902 , Qian ceng ta, Cerebra capsule, Pharmassure Memorall capsule",Alzheimer's Disease (Inactive),"Debiopharm Group™, Neuro-Hitech, Inc.",Cholinergic System,"Small Molecule, Supplement, Dietary",None,?fda_statuses[]=190&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166 | ?fda_statuses[]=190&therapy_types[]=163 | ?therapy_types[]=163
ibc-ab002,IBC-Ab002,https://www.alzforum.org/therapeutics/ibc-ab002,,Alzheimer's Disease (Phase 1),ImmunoBrain Checkpoint,"Amyloid-Related, Inflammation, Other",Immunotherapy (passive),,?fda_statuses[]=181&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=162 | ?therapy_types[]=162
ibuprofen,Ibuprofen,https://www.alzforum.org/therapeutics/ibuprofen,"Advil™, Nuprin™ , Motrin™",Alzheimer's Disease (Discontinued),,"Amyloid-Related, Inflammation",Small Molecule,Pain and Fever,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
iclepertin,Iclepertin,https://www.alzforum.org/therapeutics/iclepertin,BI 425809,"Alzheimer's Disease (Discontinued), Schizophrenia (Phase 3)",Boehringer Ingelheim,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=183&target_types[]=176 | ?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=183&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
idalopirdine,Idalopirdine,https://www.alzforum.org/therapeutics/idalopirdine,"Lu AE58054, SGS 518","Alzheimer's Disease (Discontinued), Schizophrenia (Inactive)","Lundbeck, Otsuka Pharmaceutical Co., Ltd.",Other Neurotransmitters,Small Molecule,,?fda_statuses[]=190&target_types[]=176 | ?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=190&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
idebenone,Idebenone,https://www.alzforum.org/therapeutics/idebenone,"Catena, Sovrima",Alzheimer's Disease (Discontinued),Takeda Pharmaceutical Company,Other,Small Molecule,None,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
intepirdine,Intepirdine,https://www.alzforum.org/therapeutics/intepirdine,"RVT-101, SB 742457 , GSK 742457","Alzheimer's Disease (Discontinued), Dementia with Lewy Bodies (Discontinued)",Axovant Sciences Ltd.,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
intranasal-oxytocin,Intranasal oxytocin,https://www.alzforum.org/therapeutics/intranasal-oxytocin,"Syntocinon, Pitocin",Frontotemporal Dementia (Phase 2),,Other,Other,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=167 | ?therapy_types[]=167
inzomelid,Inzomelid,https://www.alzforum.org/therapeutics/inzomelid,"Emlenoflast, IZD174, MCC-7840","Alzheimer's Disease (Discontinued), Parkinson's Disease (Discontinued)","Hoffmann-La Roche, Inflazome Ltd.",Inflammation,Small Molecule,,?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
ion464,ION464,https://www.alzforum.org/therapeutics/ion464,"BIIB101, IONIS-BIIB6Rx",Multiple System Atrophy (Discontinued),"Biogen, IONIS Pharmaceuticals",alpha-synuclein,DNA/RNA-based,,?fda_statuses[]=189&therapy_types[]=164 | ?therapy_types[]=164
ion859,ION859,https://www.alzforum.org/therapeutics/ion859,"BIIB094, IONIS-BIIB7Rx",Parkinson's Disease (Discontinued),"Biogen, IONIS Pharmaceuticals","Inflammation, Other",DNA/RNA-based,,?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=164 | ?therapy_types[]=164
irsenontrine,Irsenontrine,https://www.alzforum.org/therapeutics/irsenontrine,E2027,Dementia with Lewy Bodies (Phase 2),"Eisai Co., Ltd.",Other,Small Molecule,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
iti-1284,ITI-1284,https://www.alzforum.org/therapeutics/iti-1284,"Deulumateperone, ITI-1284-ODT-SL",Alzheimer's Disease (Phase 2),"Intra-Cellular Therapies, Inc., Johnson & Johnson",Other Neurotransmitters,Small Molecule,,?fda_statuses[]=182&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
jnj-64042056,JNJ-64042056,https://www.alzforum.org/therapeutics/jnj-64042056,"JNJ-2056, ACI-35.030 , ACI-35 , VAC20121",Alzheimer's Disease (Phase 2/3),"AC Immune SA, Janssen",Tau,Immunotherapy (active),,?fda_statuses[]=931&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=931&therapy_types[]=161 | ?therapy_types[]=161
karxt,KarXT,https://www.alzforum.org/therapeutics/karxt,"xanomeline-trospium, BMS-986510, CobenfyTM",Alzheimer's Disease (Phase 3),"Bristol-Myers Squibb, Karuna Therapeutics",Cholinergic System,"Combination, Small Molecule",Schizophrenia,?fda_statuses[]=183&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=183&therapy_types[]=36536 | ?therapy_types[]=36536 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
ketasyn,Ketasyn,https://www.alzforum.org/therapeutics/ketasyn,"Axona, Caprylic Acid, AC-1202",Alzheimer's Disease (Phase 4),Cerecin Pte. Ltd.,Other,"Supplement, Dietary",,?fda_statuses[]=851&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=851&therapy_types[]=163 | ?therapy_types[]=163
kisunla,Kisunla,https://www.alzforum.org/therapeutics/kisunla,"Donanemab, LY3002813, N3pG-Aβ Monoclonal Antibody",Alzheimer's Disease (Approved),Eli Lilly & Co.,Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=184&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=184&therapy_types[]=162 | ?therapy_types[]=162
kmct-ons,kMCT-ONS,https://www.alzforum.org/therapeutics/kmct-ons,"medium chain triglyceride-based ketogenic oral nutritional supplement, kMCT",Alzheimer's Disease (Not Regulated),Nestlé Health Science,Other,"Supplement, Dietary",,?fda_statuses[]=33161&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=33161&therapy_types[]=163 | ?therapy_types[]=163
kp405,KP405,https://www.alzforum.org/therapeutics/kp405,DA5-CH,Parkinson's Disease (Phase 1),Kariya Pharmaceuticals ApS,Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
kynmobi,Kynmobi,https://www.alzforum.org/therapeutics/kynmobi,"APL-130277, apomorphine hydrochloride sublingual thin film",Parkinson's Disease (Approved),Sunovion Pharmaceuticals Inc.,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=184&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=184&therapy_types[]=166 | ?therapy_types[]=166
ladostigil,Ladostigil,https://www.alzforum.org/therapeutics/ladostigil,"Ladostigil hemitartrate, TV3326","Mild Cognitive Impairment (Phase 2), Alzheimer's Disease (Discontinued)",Avraham Pharmaceuticals Ltd,Cholinergic System,Small Molecule,,?fda_statuses[]=182&target_types[]=172 | ?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
lamivudine,Lamivudine,https://www.alzforum.org/therapeutics/lamivudine,"3TC, Epivir",Alzheimer's Disease (Phase 2),ViiV Healthcare,Inflammation,DNA/RNA-based,"HIV infection, Hepatitis B infection",?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&therapy_types[]=164 | ?therapy_types[]=164
latozinemab,Latozinemab,https://www.alzforum.org/therapeutics/latozinemab,"AL001, GSK4527223","Frontotemporal Dementia (Discontinued), Amyotrophic Lateral Sclerosis (Inactive)","Alector, GlaxoSmithKline (GSK)",Other,Immunotherapy (passive),,?fda_statuses[]=190&target_types[]=175 | ?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=190&therapy_types[]=162 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
lenalidomide,Lenalidomide,https://www.alzforum.org/therapeutics/lenalidomide,Revlimid,Alzheimer's Disease (Phase 2),Celgene Corporation,"Amyloid-Related, Inflammation",Small Molecule,"Multiple myeloma, lymphoma, myelodysplastic syndromes",?fda_statuses[]=182&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
leqembi,Leqembi,https://www.alzforum.org/therapeutics/leqembi,"Leqembi Iqlik , Lecanemab-irmb, BAN2401, mAb158",Alzheimer's Disease (Approved),"BioArctic AB, Biogen, Eisai Co., Ltd.",Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=184&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=184&therapy_types[]=162 | ?therapy_types[]=162
leucettinib-21,Leucettinib-21,https://www.alzforum.org/therapeutics/leucettinib-21,"(R,Z)-5-(benzo[d]thiazol-6-ylmethylene)-2-((1-methoxy-4-methylpentan-2-yl)amino)-3,5-dihydro-4H-imidazol-4-one","Alzheimer's Disease (Phase 1), Down's Syndrome (Phase 1)",Perha Pharmaceuticals,Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
leuprolide,Leuprolide,https://www.alzforum.org/therapeutics/leuprolide,"Leuprolide acetate , Lupron Depot, Eligard",Alzheimer's Disease (Phase 2),"Tolmar Pharmaceuticals, Inc.",Other,Other,Advanced prostate cancer,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=167 | ?therapy_types[]=167
levetiracetam,Levetiracetam,https://www.alzforum.org/therapeutics/levetiracetam,Keppra,"Alzheimer's Disease (Phase 2), Parkinson's Disease (Discontinued)",UCB S.A.,"Amyloid-Related, Other",Small Molecule,"Epilepsy and Partial Seizures in U.S., European Union, plus about 20 other countries",?fda_statuses[]=182&target_types[]=170 | ?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=182&target_types[]=175 | ?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
levodopa,Levodopa,https://www.alzforum.org/therapeutics/levodopa,"L-Dopa, Sinemet, Duodopa, Duopa, Inbrija, Parcopa, Prolopa, Rytary, Stalevo, Crexont",Parkinson's Disease (Approved),"AbbVie, Acorda Therapeutics, Inc., Amneal Pharmaceuticals, Inc.",Other Neurotransmitters,Small Molecule,,?fda_statuses[]=184&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=184&therapy_types[]=166 | ?therapy_types[]=166
linopirdine,Linopirdine,https://www.alzforum.org/therapeutics/linopirdine,DuP996,Alzheimer's Disease (Discontinued),,Other,Small Molecule,None,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
liraglutide,Liraglutide,https://www.alzforum.org/therapeutics/liraglutide,"Victoza™, Saxenda™","Alzheimer's Disease (Phase 2), Parkinson's Disease (Phase 2)",Novo Nordisk A/S,Other,Other,"Diabetes, weight loss",?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=167 | ?therapy_types[]=167
lithium,Lithium,https://www.alzforum.org/therapeutics/lithium,"lithium carbonate, lithium aspartate, lithium citrate, lithium orotate","Alzheimer's Disease (Phase 4), Amyotrophic Lateral Sclerosis (Phase 3), Frontotemporal Dementia (Inactive), Mild Cognitive Impairment (Phase 4), Parkinson's Disease (Phase 2)",,"Amyloid-Related, Tau, Metals, Other",Other,Bipolar disorder,?fda_statuses[]=182&target_types[]=170 | ?fda_statuses[]=183&target_types[]=170 | ?fda_statuses[]=851&target_types[]=170 | ?fda_statuses[]=190&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=182&target_types[]=174 | ?fda_statuses[]=183&target_types[]=174 | ?fda_statuses[]=851&target_types[]=174 | ?fda_statuses[]=190&target_types[]=174 | ?target_types[]=174 | ?fda_statuses[]=182&target_types[]=175 | ?fda_statuses[]=183&target_types[]=175 | ?fda_statuses[]=851&target_types[]=175 | ?fda_statuses[]=190&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&target_types[]=177 | ?fda_statuses[]=183&target_types[]=177 | ?fda_statuses[]=851&target_types[]=177 | ?fda_statuses[]=190&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=182&therapy_types[]=167 | ?fda_statuses[]=183&therapy_types[]=167 | ?fda_statuses[]=851&therapy_types[]=167 | ?fda_statuses[]=190&therapy_types[]=167 | ?therapy_types[]=167
lixisenatide,Lixisenatide,https://www.alzforum.org/therapeutics/lixisenatide,"Adlyxin, Lyxumia",Parkinson's Disease (Phase 2),Sanofi,Other,Other,Type 2 diabetes,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=167 | ?therapy_types[]=167
lm11a-31-bhs,LM11A-31-BHS,https://www.alzforum.org/therapeutics/lm11a-31-bhs,LM11A-31,Alzheimer's Disease (Phase 2),PharmatrophiX,Other,Small Molecule,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
lomecel-b,Lomecel-B,https://www.alzforum.org/therapeutics/lomecel-b,mesenchymal stem cells,Alzheimer's Disease (Phase 2),Longeveron,"Inflammation, Other",Other,,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=167 | ?therapy_types[]=167
lornoxicam,Lornoxicam,https://www.alzforum.org/therapeutics/lornoxicam,,"Alzheimer's Disease (Discontinued), Mild Cognitive Impairment (Discontinued)",JSW Lifesciences,Inflammation,Small Molecule,Pain in US,?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
losartan,Losartan,https://www.alzforum.org/therapeutics/losartan,"Cozaar®, MK0954",Alzheimer's Disease (Phase 2),Merck,Other,Small Molecule,"Hypertension, diabetic neuropathy",?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
low-dose-interleukin-2,Low Dose Interleukin-2,https://www.alzforum.org/therapeutics/low-dose-interleukin-2,"COYA 301, Aldesleukin, Proleukin, ld IL-2","Alzheimer's Disease (Phase 2), Amyotrophic Lateral Sclerosis (Phase 3)",Coya Therapeutics,Inflammation,Other,,?fda_statuses[]=182&target_types[]=173 | ?fda_statuses[]=183&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&therapy_types[]=167 | ?fda_statuses[]=183&therapy_types[]=167 | ?therapy_types[]=167
low-intensity-focused-ultrasound,Low-Intensity Focused Ultrasound,https://www.alzforum.org/therapeutics/low-intensity-focused-ultrasound,"LIFU, transcranial focused ultrasound, tFUS, MR-guided Focused Ultrasound (MRgFUS)","Alzheimer's Disease (Phase 3), Mild Cognitive Impairment (Phase 2), Parkinson's Disease (Phase 2)",,"Other, Unknown",Procedural Intervention,,?fda_statuses[]=182&target_types[]=175 | ?fda_statuses[]=183&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&target_types[]=191 | ?fda_statuses[]=183&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=182&therapy_types[]=165 | ?fda_statuses[]=183&therapy_types[]=165 | ?therapy_types[]=165
lti-291,LTI-291,https://www.alzforum.org/therapeutics/lti-291,,Parkinson's Disease (Phase 2),Lysosomal Therapeutics Inc.,Other,Small Molecule,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
lu-af20513,Lu AF20513,https://www.alzforum.org/therapeutics/lu-af20513,,Alzheimer's Disease (Discontinued),"Lundbeck, Otsuka Pharmaceutical Co., Ltd.",Amyloid-Related,Immunotherapy (active),,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=161 | ?therapy_types[]=161
lu-af82422,LU AF82422,https://www.alzforum.org/therapeutics/lu-af82422,,"Parkinson's Disease (Phase 1), Multiple System Atrophy (Phase 2)","Genmab A/S, Lundbeck",alpha-synuclein,Immunotherapy (passive),,?fda_statuses[]=181&therapy_types[]=162 | ?fda_statuses[]=182&therapy_types[]=162 | ?therapy_types[]=162
lu-af87908,Lu AF87908,https://www.alzforum.org/therapeutics/lu-af87908,hC10.2,Alzheimer's Disease (Phase 1),Lundbeck,Tau,Immunotherapy (passive),,?fda_statuses[]=181&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=162 | ?therapy_types[]=162
lu-af88434,Lu AF88434,https://www.alzforum.org/therapeutics/lu-af88434,,Mild Cognitive Impairment (Discontinued),Lundbeck,Other,Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
lu25-109,LU25-109,https://www.alzforum.org/therapeutics/lu25-109,,Alzheimer's Disease (Discontinued),,Cholinergic System,Small Molecule,None,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
lumateperone,Lumateperone,https://www.alzforum.org/therapeutics/lumateperone,"Caplyta , ITI-007","Alzheimer's Disease (Discontinued), Schizophrenia (Approved), Bipolar Disorder (Approved)","Bristol-Myers Squibb, Intra-Cellular Therapies, Inc.",Other Neurotransmitters,Small Molecule,,?fda_statuses[]=184&target_types[]=176 | ?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=184&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
lx1001,LX1001,https://www.alzforum.org/therapeutics/lx1001,"AAVrh.10-APOE2, AAVrh.10hAPOE2",Alzheimer's Disease (Phase 1/2),Lexeo Therapeutics,Amyloid-Related,DNA/RNA-based,,?fda_statuses[]=33251&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=33251&therapy_types[]=164 | ?therapy_types[]=164
ly2599666,LY2599666,https://www.alzforum.org/therapeutics/ly2599666,,Alzheimer's Disease (Discontinued),Eli Lilly & Co.,Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
ly2886721,LY2886721,https://www.alzforum.org/therapeutics/ly2886721,BACE inhibitor,"Alzheimer's Disease (Discontinued), Mild Cognitive Impairment (Discontinued)",Eli Lilly & Co.,Amyloid-Related,Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
ly3202626,LY3202626,https://www.alzforum.org/therapeutics/ly3202626,BACE Inhibitor,Alzheimer's Disease (Discontinued),Eli Lilly & Co.,Amyloid-Related,Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
ly3884961,LY3884961,https://www.alzforum.org/therapeutics/ly3884961,"PR001, PR001A",Parkinson's Disease (Phase 1/2),"Eli Lilly & Co., Prevail Therapeutics",Other,DNA/RNA-based,,?fda_statuses[]=33251&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=33251&therapy_types[]=164 | ?therapy_types[]=164
ly3884963,LY3884963,https://www.alzforum.org/therapeutics/ly3884963,PR006,Frontotemporal Dementia (Phase 1/2),"Eli Lilly & Co., Prevail Therapeutics",Other,DNA/RNA-based,,?fda_statuses[]=33251&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=33251&therapy_types[]=164 | ?therapy_types[]=164
ly3954068,LY3954068,https://www.alzforum.org/therapeutics/ly3954068,,Alzheimer's Disease (Phase 1),Eli Lilly & Co.,Tau,DNA/RNA-based,,?fda_statuses[]=181&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=164 | ?therapy_types[]=164
ly3962681,LY3962681,https://www.alzforum.org/therapeutics/ly3962681,,Parkinson's Disease (Phase 1),"Eli Lilly & Co., Prevail Therapeutics",alpha-synuclein,DNA/RNA-based,,?fda_statuses[]=181&therapy_types[]=164 | ?therapy_types[]=164
masitinib,Masitinib,https://www.alzforum.org/therapeutics/masitinib,"Masivet, Kinavet, AB1010, Masitinib mesylate","Alzheimer's Disease (Phase 3), Amyotrophic Lateral Sclerosis (Phase 3)",AB Science,Other,Small Molecule,,?fda_statuses[]=183&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
masupirdine,Masupirdine,https://www.alzforum.org/therapeutics/masupirdine,SUVN-502,Alzheimer's Disease (Phase 3),Suven Life Sciences Ltd,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=183&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
medi1814,MEDI1814,https://www.alzforum.org/therapeutics/medi1814,,Alzheimer's Disease (Discontinued),"AstraZeneca, Eli Lilly & Co.",Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
melatonin,Melatonin,https://www.alzforum.org/therapeutics/melatonin,,Alzheimer's Disease (Phase 2),,Other,"Supplement, Dietary",None,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=163 | ?therapy_types[]=163
mem-1003,MEM 1003,https://www.alzforum.org/therapeutics/mem-1003,BAY Z 4406,"Alzheimer's Disease (Discontinued), Mild Cognitive Impairment (Discontinued), Vascular Dementia (Discontinued), Bipolar Disorder (Discontinued)",Memory Pharmaceuticals Corporation,Other,Small Molecule,None,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
memantine,Memantine,https://www.alzforum.org/therapeutics/memantine,"Ebixa™, Namenda™ , Axura®, Akatinol®, Memary®",Alzheimer's Disease (Approved),"Forest Laboratories, Inc., Lundbeck, Merz Pharma",Other Neurotransmitters,Small Molecule,Alzheimer's Disease,?fda_statuses[]=184&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=184&therapy_types[]=166 | ?therapy_types[]=166
memorem-transcranial-electromagnetic-treatment,MemorEM Transcranial Electromagnetic Treatment,https://www.alzforum.org/therapeutics/memorem-transcranial-electromagnetic-treatment,TEMT,Alzheimer's Disease (Phase 1),"NeuroEM Therapeutics, Inc.","Amyloid-Related, Other",Procedural Intervention,,?fda_statuses[]=181&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=165 | ?therapy_types[]=165
metformin,Metformin,https://www.alzforum.org/therapeutics/metformin,"Glucophage, Glucophage XR",Alzheimer's Disease (Phase 2/3),,Other,Small Molecule,Type 2 Diabetes,?fda_statuses[]=931&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=931&therapy_types[]=166 | ?therapy_types[]=166
methylphenidate,Methylphenidate,https://www.alzforum.org/therapeutics/methylphenidate,"Ritalin, Concerta",Alzheimer's Disease (Phase 4),,Other Neurotransmitters,Small Molecule,"Attention-deficit hyperactivity disorder (ADHD), narcolepsy",?fda_statuses[]=851&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=851&therapy_types[]=166 | ?therapy_types[]=166
metrifonate,Metrifonate,https://www.alzforum.org/therapeutics/metrifonate,trichlorfon,Alzheimer's Disease (Discontinued),,Cholinergic System,Small Molecule,None,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
mevidalen,Mevidalen,https://www.alzforum.org/therapeutics/mevidalen,"LY3154207, Mevidalen hydroxybenzoate","Parkinson's Disease Dementia (Phase 2), Dementia with Lewy Bodies (Phase 2)",Eli Lilly & Co.,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=182&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
milameline,Milameline,https://www.alzforum.org/therapeutics/milameline,CI 979,Alzheimer's Disease (Discontinued),"Aventis Pharmaceuticals, Inc. (was Hoechst)",Cholinergic System,Small Molecule,None,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
minocycline,Minocycline,https://www.alzforum.org/therapeutics/minocycline,"Solodyn, Arestin, Minocin, Dynacin",Alzheimer's Disease (Discontinued),,Other,Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
minzasolmin,Minzasolmin,https://www.alzforum.org/therapeutics/minzasolmin,"UCB0599, NPT200-11",Parkinson's Disease (Discontinued),"Neuropore Therapies, Inc., Novartis Pharmaceuticals Corporation, UCB S.A.",alpha-synuclein,Small Molecule,,?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
mirtazapine,Mirtazapine,https://www.alzforum.org/therapeutics/mirtazapine,"Remeron, esmirtazapine, Org 50081",Alzheimer's Disease (Phase 3),,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=183&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
mivelsiran,Mivelsiran,https://www.alzforum.org/therapeutics/mivelsiran,ALN-APP,"Alzheimer's Disease (Phase 1), Cerebral Amyloid Angiopathy (Phase 2)","Alnylam Pharmaceuticals, Inc.",Amyloid-Related,DNA/RNA-based,,?fda_statuses[]=181&target_types[]=170 | ?fda_statuses[]=182&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&therapy_types[]=164 | ?fda_statuses[]=182&therapy_types[]=164 | ?therapy_types[]=164
mk-1167,MK-1167,https://www.alzforum.org/therapeutics/mk-1167,,Alzheimer's Disease (Phase 2),"Merck, Neuphoria Therapeutics",Cholinergic System,Small Molecule,,?fda_statuses[]=182&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
mk-1942,MK-1942,https://www.alzforum.org/therapeutics/mk-1942,,Alzheimer's Disease (Discontinued),Merck,Unknown,Small Molecule,,?fda_statuses[]=189&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
mk-2214,MK-2214,https://www.alzforum.org/therapeutics/mk-2214,,Alzheimer's Disease (Phase 2),Merck,Tau,Immunotherapy (passive),,?fda_statuses[]=182&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=182&therapy_types[]=162 | ?therapy_types[]=162
mk-7622,MK-7622,https://www.alzforum.org/therapeutics/mk-7622,,Alzheimer's Disease (Discontinued),Merck,Unknown,Small Molecule,,?fda_statuses[]=189&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
mk-8189,MK-8189,https://www.alzforum.org/therapeutics/mk-8189,,Alzheimer's Disease (Phase 1),Merck,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=181&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
mkc-231,MKC-231,https://www.alzforum.org/therapeutics/mkc-231,,Alzheimer's Disease (Inactive),Mitsubishi Tanabe Pharma,Unknown,Small Molecule,None,?fda_statuses[]=190&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
montelukast,Montelukast,https://www.alzforum.org/therapeutics/montelukast,"Singulair, MK0476","Alzheimer's Disease (Phase 2), Parkinson's Disease (Phase 2)",Intelgenx,Inflammation,Small Molecule,Asthma,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
msdc-0160,MSDC-0160,https://www.alzforum.org/therapeutics/msdc-0160,Mitoglitazone,Alzheimer's Disease (Phase 2),Metabolic Solutions Development Company,Other,Small Molecule,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
multivitamin-mineral-supplement,Multivitamin-mineral Supplement,https://www.alzforum.org/therapeutics/multivitamin-mineral-supplement,Centrum Silver,Mild Cognitive Impairment (Not Regulated),Pfizer,Other,"Supplement, Dietary",,?fda_statuses[]=33161&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=33161&therapy_types[]=163 | ?therapy_types[]=163
mw150-0,MW150,https://www.alzforum.org/therapeutics/mw150-0,MW01-18-150SRM,Alzheimer's Disease (Phase 2),Neurokine Therapeutics,"Inflammation, Other",Small Molecule,,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
mw151,MW151,https://www.alzforum.org/therapeutics/mw151,"MW01-2-151SRM, Minozac, MW01-2-151WH, compound 17",Alzheimer's Disease (Phase 1),"ImmunoChem Therapeutics, LLC",Inflammation,Small Molecule,,?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
na-831,NA-831,https://www.alzforum.org/therapeutics/na-831,Traneurocin,Alzheimer's Disease (Phase 2),"Biomed Industries, NeuroActiva™ Inc.",Cholinergic System,Small Molecule,,?fda_statuses[]=182&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
nabilone,Nabilone,https://www.alzforum.org/therapeutics/nabilone,Cesamet,"Alzheimer's Disease (Phase 3), Parkinson's Disease (Phase 2)",Bausch Health Companies Inc.,Other Neurotransmitters,Small Molecule,Nausea associated with cancer chemotherapy (US and other countries); pain spasticity in multiple sclerosis (Canada and other countries).,?fda_statuses[]=182&target_types[]=176 | ?fda_statuses[]=183&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
naproxen,Naproxen,https://www.alzforum.org/therapeutics/naproxen,"Aleve™, Anaprox™, Naprosyn™",Alzheimer's Disease (Discontinued),Procter & Gamble,Inflammation,Small Molecule,"Over-the-counter drug for reduction of pain, fever, inflammation, and stiffness.",?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
nasal-insulin,Nasal Insulin,https://www.alzforum.org/therapeutics/nasal-insulin,"Detemir, Levemir, Humulin, Novolin, glulisine","Alzheimer's Disease (Phase 2/3), Mild Cognitive Impairment (Phase 2), Parkinson's Disease (Phase 2), Multiple System Atrophy (Phase 2)",,"Amyloid-Related, Other","Small Molecule, Other",Diabetes,?fda_statuses[]=182&target_types[]=170 | ?fda_statuses[]=931&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=182&target_types[]=175 | ?fda_statuses[]=931&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=167 | ?fda_statuses[]=931&therapy_types[]=167 | ?therapy_types[]=167 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=931&therapy_types[]=166 | ?therapy_types[]=166
nb-4746,NB-4746,https://www.alzforum.org/therapeutics/nb-4746,,Amyotrophic Lateral Sclerosis (Phase 1),Nura Bio™ Inc.,Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
nefiracetam,Nefiracetam,https://www.alzforum.org/therapeutics/nefiracetam,,Alzheimer's Disease (Discontinued),Daiichi Sankyo Pharmaceuticals,Cholinergic System,Small Molecule,None,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
neflamapimod,Neflamapimod,https://www.alzforum.org/therapeutics/neflamapimod,VX-745,"Alzheimer's Disease (Phase 2), Dementia with Lewy Bodies (Phase 2), Huntington's Disease (Discontinued)","CervoMed, Inc.",Inflammation,Small Molecule,,?fda_statuses[]=182&target_types[]=173 | ?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
nelonicline,Nelonicline,https://www.alzforum.org/therapeutics/nelonicline,ABT-126,"Alzheimer's Disease (Discontinued), Schizophrenia (Inactive)",AbbVie,Cholinergic System,Small Molecule,,?fda_statuses[]=190&target_types[]=172 | ?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=190&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
nelotanserin,Nelotanserin,https://www.alzforum.org/therapeutics/nelotanserin,APD-125,Dementia with Lewy Bodies (Discontinued),Axovant Sciences Ltd.,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
neotrofin,NeoTrofin,https://www.alzforum.org/therapeutics/neotrofin,"AIT-082, leteprinim",Alzheimer's Disease (Discontinued),"NeoTherapeutics, Inc.",Unknown,Small Molecule,None,?fda_statuses[]=189&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
neramexane,Neramexane,https://www.alzforum.org/therapeutics/neramexane,MRZ 2/579,Alzheimer's Disease (Discontinued),"Forest Laboratories, Inc., Merck",Other Neurotransmitters,Small Molecule,None,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
neu-411,NEU-411,https://www.alzforum.org/therapeutics/neu-411,,Parkinson's Disease (Phase 2),Neuron23,"Inflammation, Other",Small Molecule,,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
neuroad,NeuroAD,https://www.alzforum.org/therapeutics/neuroad,"Repetitive Transcranial Magnetic Stimulation , rTMS-Cog",Alzheimer's Disease (Rejected),Neuronix Ltd,Other,Procedural Intervention,,?fda_statuses[]=40686&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=40686&therapy_types[]=165 | ?therapy_types[]=165
nic5-15,NIC5-15,https://www.alzforum.org/therapeutics/nic5-15,"Pinitol, D-Pinitol",Alzheimer's Disease (Phase 2),Humanetics Pharmaceuticals Corporation,"Amyloid-Related, Other","Small Molecule, Supplement, Dietary",,?fda_statuses[]=182&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166 | ?fda_statuses[]=182&therapy_types[]=163 | ?therapy_types[]=163
nicotinamide-riboside,Nicotinamide Riboside,https://www.alzforum.org/therapeutics/nicotinamide-riboside,"Niagen, NR, Nicotinamide, Vitamin B3","Alzheimer's Disease (Phase 1), Parkinson's Disease (Phase 2), Mild Cognitive Impairment (Phase 1/2)","ChromaDex, Others",Other,"Supplement, Dietary",,?fda_statuses[]=181&target_types[]=175 | ?fda_statuses[]=33251&target_types[]=175 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=163 | ?fda_statuses[]=33251&therapy_types[]=163 | ?fda_statuses[]=182&therapy_types[]=163 | ?therapy_types[]=163
nilotinib,Nilotinib,https://www.alzforum.org/therapeutics/nilotinib,"Tasigna, AMN107","Parkinson's Disease (Phase 2), Dementia with Lewy Bodies (Phase 2), Alzheimer's Disease (Inactive)",KeifeRx,Other,Small Molecule,Chronic myeloid leukemia,?fda_statuses[]=182&target_types[]=175 | ?fda_statuses[]=190&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
nilvadipine,Nilvadipine,https://www.alzforum.org/therapeutics/nilvadipine,"Nilvad, Nivadil, ARC029",Alzheimer's Disease (Inactive),"Archer Pharmaceuticals, Inc.",Other,Small Molecule,,?fda_statuses[]=190&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
nimodipine,Nimodipine,https://www.alzforum.org/therapeutics/nimodipine,Nimotop,Frontotemporal Dementia (Discontinued),Bayer,Metals,Small Molecule,Subarachnoid hemorrhage,?fda_statuses[]=189&target_types[]=174 | ?target_types[]=174 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
nio752,NIO752,https://www.alzforum.org/therapeutics/nio752,,"Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 1)",Novartis Pharmaceuticals Corporation,Tau,DNA/RNA-based,,?fda_statuses[]=181&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=164 | ?therapy_types[]=164
nivegacetor,Nivegacetor,https://www.alzforum.org/therapeutics/nivegacetor,"RG6289 , RO7269162",Alzheimer's Disease (Phase 2/3),Hoffmann-La Roche,Amyloid-Related,Small Molecule,,?fda_statuses[]=931&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=931&therapy_types[]=166 | ?therapy_types[]=166
nmra-511,NMRA-511,https://www.alzforum.org/therapeutics/nmra-511,NMRA-323511,Alzheimer's Disease (Phase 1),Neumora,Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
npt520-34,NPT520-34,https://www.alzforum.org/therapeutics/npt520-34,,"Amyotrophic Lateral Sclerosis (Phase 1), Parkinson's Disease (Phase 1)","Neuropore Therapies, Inc.","alpha-synuclein, Inflammation, Other",Small Molecule,,?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
ns2330,NS2330,https://www.alzforum.org/therapeutics/ns2330,Tesofensine,Alzheimer's Disease (Discontinued),NeuroSearch A/S,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
nsc001,NSC001,https://www.alzforum.org/therapeutics/nsc001,"AF267B , NGX267, NI004",Alzheimer's Disease (Phase 1/2),"Neurimmune, TorreyPines Therapeutics, Inc.",Cholinergic System,Small Molecule,None,?fda_statuses[]=33251&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=33251&therapy_types[]=166 | ?therapy_types[]=166
nt-0796,NT-0796,https://www.alzforum.org/therapeutics/nt-0796,"Propan-2-yl (2R)-2-{[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)- carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoate",Parkinson's Disease (Phase 1/2),NodThera,Inflammation,Small Molecule,,?fda_statuses[]=33251&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=33251&therapy_types[]=166 | ?therapy_types[]=166
ntrx-07,NTRX-07,https://www.alzforum.org/therapeutics/ntrx-07,MDA7,Alzheimer's Disease (Phase 1),"NeuroTherapia, Inc.","Inflammation, Other",Small Molecule,,?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
nuplazid,Nuplazid,https://www.alzforum.org/therapeutics/nuplazid,"Pimavanserin, ACP-103, Pimavanserin tartrate","Alzheimer's Disease (Rejected), Schizophrenia (Discontinued), Dementia (Rejected), Depression (Discontinued)",Acadia Pharmaceuticals,Other Neurotransmitters,Small Molecule,Parkinson's psychosis,?fda_statuses[]=40686&target_types[]=176 | ?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=40686&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
nurowntm,NurOwn™,https://www.alzforum.org/therapeutics/nurowntm,"MSC-NTF Cells, debamestrocel , Neurotrophic factors-secreting Mesenchymal Stromal Cells",Amyotrophic Lateral Sclerosis (Phase 3),"BrainStorm Cell Therapeutics, Inc.",Other,Other,,?fda_statuses[]=183&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=183&therapy_types[]=167 | ?therapy_types[]=167
nuz-001,NUZ-001,https://www.alzforum.org/therapeutics/nuz-001,"S-Monepantel, Zolvix®",Amyotrophic Lateral Sclerosis (Phase 1),Neurizon Therapeutics,Other,Small Molecule,Deworming sheep,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
nx210c,NX210c,https://www.alzforum.org/therapeutics/nx210c,HWSGWSS[CSRSC]GOH (brackets represent the disulfide bond),"Amyotrophic Lateral Sclerosis (Phase 2), Parkinson's Disease (Phase 1)",Axoltis Pharma,Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
nyx-458,NYX-458,https://www.alzforum.org/therapeutics/nyx-458,,PD-MCI (Discontinued),Aptinyx Inc.,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
obicetrapib,Obicetrapib,https://www.alzforum.org/therapeutics/obicetrapib,TA-8995,Alzheimer's Disease (Phase 2),NewAmsterdam Pharma,Cholesterol,Small Molecule,,?fda_statuses[]=182&target_types[]=171 | ?target_types[]=171 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
octagam%C2%AE,Octagam®10%,https://www.alzforum.org/therapeutics/octagam%C2%AE,"Intravenous Immunoglobulin, NewGam","Alzheimer's Disease (Inactive), Mild Cognitive Impairment (Inactive)",Octapharma,"Amyloid-Related, Inflammation",Immunotherapy (passive),Immunodeficiency disorders,?fda_statuses[]=190&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=190&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=190&therapy_types[]=162 | ?therapy_types[]=162
olx-07010,OLX-07010,https://www.alzforum.org/therapeutics/olx-07010,,Alzheimer's Disease (Phase 1),"Oligomerix, Inc.",Tau,Small Molecule,,?fda_statuses[]=181&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
opm-201,OPM-201,https://www.alzforum.org/therapeutics/opm-201,S221237,Parkinson's Disease (Phase 1),Oncodesign Precision Medicine,Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
orm-12741,ORM-12741,https://www.alzforum.org/therapeutics/orm-12741,,Alzheimer's Disease (Phase 2),Orion Pharma,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=182&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
pbft02,PBFT02,https://www.alzforum.org/therapeutics/pbft02,,Frontotemporal Dementia (Phase 1/2),Passage Bio,Other,DNA/RNA-based,,?fda_statuses[]=33251&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=33251&therapy_types[]=164 | ?therapy_types[]=164
pbt2,PBT2,https://www.alzforum.org/therapeutics/pbt2,PBT-2,"Alzheimer's Disease (Inactive), Huntington's Disease (Inactive)",Alterity Therapeutics,"Amyloid-Related, Metals",Small Molecule,,?fda_statuses[]=190&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=190&target_types[]=174 | ?target_types[]=174 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
pepinemab,Pepinemab,https://www.alzforum.org/therapeutics/pepinemab,"VX15, VX15/2503","Alzheimer's Disease (Phase 1/2), Huntington's Disease (Phase 2)","Vaccinex, Inc.",Inflammation,Immunotherapy (passive),,?fda_statuses[]=33251&target_types[]=173 | ?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=33251&therapy_types[]=162 | ?fda_statuses[]=182&therapy_types[]=162 | ?therapy_types[]=162
pf-05212377,PF-05212377,https://www.alzforum.org/therapeutics/pf-05212377,"PF-5212377, WYE-103760, SAM-760",Alzheimer's Disease (Discontinued),Pfizer,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
pf-06648671,PF-06648671,https://www.alzforum.org/therapeutics/pf-06648671,,Alzheimer's Disease (Discontinued),Pfizer,Amyloid-Related,Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
pf-06751979,PF-06751979,https://www.alzforum.org/therapeutics/pf-06751979,BACE inhibitor,Alzheimer's Disease (Discontinued),Pfizer,Amyloid-Related,Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
pf-06852231,PF-06852231,https://www.alzforum.org/therapeutics/pf-06852231,,Alzheimer's Disease (Discontinued),Pfizer,Cholinergic System,Small Molecule,,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
phenserine,Phenserine,https://www.alzforum.org/therapeutics/phenserine,,Alzheimer's Disease (Inactive),"Annovis Bio, TorreyPines Therapeutics, Inc.",Cholinergic System,Small Molecule,,?fda_statuses[]=190&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
photobiomodulation,PhotoBioModulation,https://www.alzforum.org/therapeutics/photobiomodulation,"Low level light therapy, Low level laser therapy, Cold laser therapy, Transcranial infrared brain stimulation, Transcranial photobiomodulation, Transcranial near-infrared laser therapy (NILT), Transcranial low-level light therapy","Alzheimer's Disease (Not Regulated), Mild Cognitive Impairment (Not Regulated), Parkinson's Disease (Not Regulated)",,"Inflammation, Unknown",Procedural Intervention,,?fda_statuses[]=33161&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=33161&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=33161&therapy_types[]=165 | ?therapy_types[]=165
physostigmine-salicylate,Physostigmine Salicylate,https://www.alzforum.org/therapeutics/physostigmine-salicylate,Synapton,Alzheimer's Disease (Discontinued),"Forest Laboratories, Inc.",Cholinergic System,Small Molecule,,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
pioglitazone,Pioglitazone,https://www.alzforum.org/therapeutics/pioglitazone,"AD4833, Actos®, Glustin™, Piozone®",Mild Cognitive Impairment (Phase 3),"Takeda Pharmaceutical Company, Zinfandel Pharmaceuticals Inc.","Inflammation, Other",Small Molecule,Type 2 diabetes mellitus,?fda_statuses[]=183&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=183&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
piromelatine,Piromelatine,https://www.alzforum.org/therapeutics/piromelatine,Neu-P11,Alzheimer's Disease (Phase 2),Neurim Pharmaceuticals Ltd.,"Other Neurotransmitters, Other",Small Molecule,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
pmn310,PMN310,https://www.alzforum.org/therapeutics/pmn310,,Alzheimer's Disease (Phase 1),"ProMIS Neurosciences, Inc.",Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=181&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&therapy_types[]=162 | ?therapy_types[]=162
pnt001,PNT001,https://www.alzforum.org/therapeutics/pnt001,,"Alzheimer's Disease (Inactive), Traumatic Brain Injury (Inactive)",Pinteon Therapeutics,Tau,Immunotherapy (passive),,?fda_statuses[]=190&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=190&therapy_types[]=162 | ?therapy_types[]=162
ponezumab,Ponezumab,https://www.alzforum.org/therapeutics/ponezumab,PF-04360365,"Alzheimer's Disease (Discontinued), Cerebral Amyloid Angiopathy (Discontinued)",Pfizer,Amyloid-Related,Immunotherapy (passive),None,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
posdinemab,Posdinemab,https://www.alzforum.org/therapeutics/posdinemab,JNJ-63733657,Mild AD (Phase 2),Janssen,Tau,Immunotherapy (passive),,?fda_statuses[]=182&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=182&therapy_types[]=162 | ?therapy_types[]=162
prasinezumab,Prasinezumab,https://www.alzforum.org/therapeutics/prasinezumab,"PRX002, RO7046015, RG7935, NEOD002",Parkinson's Disease (Phase 2),"Hoffmann-La Roche, Prothena",alpha-synuclein,Immunotherapy (passive),,?fda_statuses[]=182&therapy_types[]=162 | ?therapy_types[]=162
prazosin,Prazosin,https://www.alzforum.org/therapeutics/prazosin,"Prazosin hydrochloride, Minipress, Hypovase, Vasoflex",Alzheimer's Disease (Phase 4),,Other Neurotransmitters,Small Molecule,Hypertension,?fda_statuses[]=851&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=851&therapy_types[]=166 | ?therapy_types[]=166
prednisone,Prednisone,https://www.alzforum.org/therapeutics/prednisone,,Alzheimer's Disease (Discontinued),,Inflammation,Small Molecule,,?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
pri-002,PRI-002,https://www.alzforum.org/therapeutics/pri-002,"Contraloid, contraloid acetate, RD2",Alzheimer's Disease (Phase 1),Priavoid GmbH,Amyloid-Related,Small Molecule,,?fda_statuses[]=181&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
pridopidine,Pridopidine,https://www.alzforum.org/therapeutics/pridopidine,"ACR16, TV-7820, Huntexil, ASP2314","Amyotrophic Lateral Sclerosis (Phase 2/3), Huntington's Disease (Phase 3), Parkinson's Disease (Inactive)",Prilenia Therapeutics,Other,Small Molecule,,?fda_statuses[]=931&target_types[]=175 | ?fda_statuses[]=183&target_types[]=175 | ?fda_statuses[]=190&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=931&therapy_types[]=166 | ?fda_statuses[]=183&therapy_types[]=166 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
primec,PrimeC,https://www.alzforum.org/therapeutics/primec,Ciprofloxacin and Celecoxib,Alzheimer's Disease (Phase 2),NeuroSense Therapeutics,"Inflammation, Metals, Other",Combination,,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&target_types[]=174 | ?target_types[]=174 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=36536 | ?therapy_types[]=36536
propentofylline,Propentofylline,https://www.alzforum.org/therapeutics/propentofylline,"HWA 285, PPF",Alzheimer's Disease (Discontinued),,Unknown,Small Molecule,,?fda_statuses[]=189&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
protollin,Protollin,https://www.alzforum.org/therapeutics/protollin,,Alzheimer's Disease (Phase 1),"I-MAB Biopharma Co., Ltd., Jiangsu Nhwa Pharmaceutical Co., Ltd",Inflammation,Immunotherapy (active),,?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&therapy_types[]=161 | ?therapy_types[]=161
prx-03140,PRX-03140,https://www.alzforum.org/therapeutics/prx-03140,Potassium salt,Alzheimer's Disease (Inactive),Epix Pharmaceuticals,Other,Small Molecule,,?fda_statuses[]=190&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
prx012,PRX012,https://www.alzforum.org/therapeutics/prx012,,Alzheimer's Disease (Inactive),Prothena,Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=190&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=190&therapy_types[]=162 | ?therapy_types[]=162
pu-ad,PU-AD,https://www.alzforum.org/therapeutics/pu-ad,"PU-HZ151, icapamespib",Alzheimer's Disease (Phase 2),Samus Therapeutics,Other,Small Molecule,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
pxt864,PXT864,https://www.alzforum.org/therapeutics/pxt864,PXT00864,Alzheimer's Disease (Discontinued),Pharnext,Other Neurotransmitters,"Combination, Small Molecule",,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=36536 | ?therapy_types[]=36536 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
qalsodytm,QALSODY™,https://www.alzforum.org/therapeutics/qalsodytm,"Tofersen, BIIB067, Ionis-SOD1Rx , ASO1",Amyotrophic Lateral Sclerosis (Approved),"Biogen, IONIS Pharmaceuticals",Other,DNA/RNA-based,ALS,?fda_statuses[]=184&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=184&therapy_types[]=164 | ?therapy_types[]=164
qrl-101,QRL-101,https://www.alzforum.org/therapeutics/qrl-101,QRA-244,Amyotrophic Lateral Sclerosis (Phase 1),QurAlis Corporation,Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
qrl-201,QRL-201,https://www.alzforum.org/therapeutics/qrl-201,,Amyotrophic Lateral Sclerosis (Phase 1),QurAlis Corporation,Other,DNA/RNA-based,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=164 | ?therapy_types[]=164
rasagiline,Rasagiline,https://www.alzforum.org/therapeutics/rasagiline,"Rasagiline mesylate, Azilect, TVP-1012","Alzheimer's Disease (Phase 2), Parkinson's Disease (Approved), Amyotrophic Lateral Sclerosis (Inactive)",Teva,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=182&target_types[]=176 | ?fda_statuses[]=184&target_types[]=176 | ?fda_statuses[]=190&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=184&therapy_types[]=166 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
relyvrio,Relyvrio,https://www.alzforum.org/therapeutics/relyvrio,"Albrioza, AMX0035","Amyotrophic Lateral Sclerosis (Withdrawn), Alzheimer's Disease (Inactive), Progressive Supranuclear Palsy (Discontinued)",Amylyx Pharmaceuticals Inc,Other,"Combination, Small Molecule",ALS,?fda_statuses[]=190&target_types[]=175 | ?fda_statuses[]=189&target_types[]=175 | ?fda_statuses[]=41421&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=190&therapy_types[]=36536 | ?fda_statuses[]=189&therapy_types[]=36536 | ?fda_statuses[]=41421&therapy_types[]=36536 | ?therapy_types[]=36536 | ?fda_statuses[]=190&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?fda_statuses[]=41421&therapy_types[]=166 | ?therapy_types[]=166
rem0045392,REM0045392,https://www.alzforum.org/therapeutics/rem0045392,REM392,Alzheimer's Disease (Phase 1),remynd,Tau,Small Molecule,,?fda_statuses[]=181&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
rember-tm,Rember TM,https://www.alzforum.org/therapeutics/rember-tm,"Methylene Blue , methylthioninium (MT), TRx-0014, Tau aggregation inhibitor (TAI)",Alzheimer's Disease (Discontinued),TauRx Therapeutics Ltd,Tau,Small Molecule,Methylene Blue predates FDA. Used for treatment of malaria and methemoglobinemia.,?fda_statuses[]=189&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
remternetug,Remternetug,https://www.alzforum.org/therapeutics/remternetug,"LY3372993, N3pG-Abeta mAb",Alzheimer's Disease (Phase 3),Eli Lilly & Co.,Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=183&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=183&therapy_types[]=162 | ?therapy_types[]=162
resveratrol,Resveratrol,https://www.alzforum.org/therapeutics/resveratrol,"trans-3,4',5-trihydroxystilbene","Alzheimer's Disease (Phase 3), Mild Cognitive Impairment (Phase 4)",,Other,"Small Molecule, Supplement, Dietary",,?fda_statuses[]=183&target_types[]=175 | ?fda_statuses[]=851&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=183&therapy_types[]=166 | ?fda_statuses[]=851&therapy_types[]=166 | ?therapy_types[]=166 | ?fda_statuses[]=183&therapy_types[]=163 | ?fda_statuses[]=851&therapy_types[]=163 | ?therapy_types[]=163
rg3487,RG3487,https://www.alzforum.org/therapeutics/rg3487,"RO5313534, MEM 3454",Alzheimer's Disease (Inactive),,Cholinergic System,Small Molecule,,?fda_statuses[]=190&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
rg7129,RG7129,https://www.alzforum.org/therapeutics/rg7129,"RO5508887, BACE Inhibitor",Alzheimer's Disease (Discontinued),Roche,Amyloid-Related,Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
rg7345,RG7345,https://www.alzforum.org/therapeutics/rg7345,RO6926496,Alzheimer's Disease (Discontinued),,Tau,Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
rilapladib,Rilapladib,https://www.alzforum.org/therapeutics/rilapladib,SB-659032,Alzheimer's Disease (Discontinued),GlaxoSmithKline (GSK),Other,Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
riluzole,Riluzole,https://www.alzforum.org/therapeutics/riluzole,"Rilutek®, RP 54274","Alzheimer's Disease (Phase 2), Parkinson's Disease (Discontinued), Amyotrophic Lateral Sclerosis (Approved), Huntington's Disease (Discontinued)",Sanofi,"Other Neurotransmitters, Other",Small Molecule,Amyotrophic Lateral Sclerosis in many countries,?fda_statuses[]=182&target_types[]=175 | ?fda_statuses[]=184&target_types[]=175 | ?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&target_types[]=176 | ?fda_statuses[]=184&target_types[]=176 | ?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=184&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
risvodetinib,Risvodetinib,https://www.alzforum.org/therapeutics/risvodetinib,IkT-148009,Parkinson's Disease (Phase 2),"Inhibikase Therapeutics, Inc.","alpha-synuclein, Other",Small Molecule,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
rivastigmine,Rivastigmine,https://www.alzforum.org/therapeutics/rivastigmine,"Exelon™, Rivastigmine tartrate , Rivastach® Patch, Prometax®, SDZ ENA 713","Alzheimer's Disease (Approved), Parkinson's Disease Dementia (Approved)",Novartis Pharmaceuticals Corporation,Cholinergic System,Small Molecule,Mild to moderate Alzheimer’s disease and mild to moderate dementia related to Parkinson's disease,?fda_statuses[]=184&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=184&therapy_types[]=166 | ?therapy_types[]=166
rns60,RNS60,https://www.alzforum.org/therapeutics/rns60,oxygen nanobubbles,Amyotrophic Lateral Sclerosis (Phase 2),Revalesio Corporation,"Inflammation, Other",Other,,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=167 | ?therapy_types[]=167
rofecoxib,Rofecoxib,https://www.alzforum.org/therapeutics/rofecoxib,Vioxx™,Alzheimer's Disease (Discontinued),Merck,Inflammation,Small Molecule,Withdrawn from market,?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
rosiglitazone,Rosiglitazone,https://www.alzforum.org/therapeutics/rosiglitazone,"Rosiglitazone maleate, Avandia",Alzheimer's Disease (Discontinued),GlaxoSmithKline (GSK),Other,Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
rotigotine,Rotigotine,https://www.alzforum.org/therapeutics/rotigotine,Neupro,"Alzheimer's Disease (Phase 2), Frontotemporal Dementia (Phase 2)",UCB S.A.,Other Neurotransmitters,Small Molecule,"Parkinson's disease, Restless Leg Syndrome",?fda_statuses[]=182&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
s-38093,S 38093,https://www.alzforum.org/therapeutics/s-38093,,Alzheimer's Disease (Discontinued),Servier,"Cholinergic System, Other Neurotransmitters",Small Molecule,,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
s-equol,S-Equol,https://www.alzforum.org/therapeutics/s-equol,Aus-131,Alzheimer's Disease (Phase 1),"Ausio Pharmaceuticals, LLC",Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
s47445,S47445,https://www.alzforum.org/therapeutics/s47445,CX1632,Alzheimer's Disease (Discontinued),"Cortex Pharmaceuticals, Inc., Servier",Other Neurotransmitters,Small Molecule,,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
s603,AS-S603,https://www.alzforum.org/therapeutics/s603,,"Alzheimer's Disease (Phase 1), Mild Cognitive Impairment (Phase 1)",Amyloid Solution Inc.,"Amyloid-Related, Tau",Small Molecule,,?fda_statuses[]=181&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
sabeluzole,Sabeluzole,https://www.alzforum.org/therapeutics/sabeluzole,R58735,Alzheimer's Disease (Inactive),,Unknown,Small Molecule,,?fda_statuses[]=190&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
sabirnetug,Sabirnetug,https://www.alzforum.org/therapeutics/sabirnetug,ACU-193,Alzheimer's Disease (Phase 2/3),"Acumen Pharmaceuticals, Inc.",Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=931&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=931&therapy_types[]=162 | ?therapy_types[]=162
safinamide,Safinamide,https://www.alzforum.org/therapeutics/safinamide,"Xadago, Onstryv","Multiple System Atrophy (Phase 2), Parkinson's Disease (Approved)","Newron, Zambon Company S.p.A.",Other Neurotransmitters,Small Molecule,,?fda_statuses[]=182&target_types[]=176 | ?fda_statuses[]=184&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=184&therapy_types[]=166 | ?therapy_types[]=166
sage-718,SAGE-718,https://www.alzforum.org/therapeutics/sage-718,Dalzanemdor,"Alzheimer's Disease (Phase 2), Parkinson's Disease (Discontinued), Huntington's Disease (Phase 2)","Sage Therapeutics, Inc.",Other Neurotransmitters,Small Molecule,,?fda_statuses[]=182&target_types[]=176 | ?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
sar110894d,SAR110894D,https://www.alzforum.org/therapeutics/sar110894d,,Alzheimer's Disease (Phase 2),Sanofi,Other,Small Molecule,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
sar228810,SAR228810,https://www.alzforum.org/therapeutics/sar228810,,Alzheimer's Disease (Discontinued),Sanofi,Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
sar446159,SAR446159,https://www.alzforum.org/therapeutics/sar446159,"ABL301, SynucleinxIGF1R mAb",Parkinson's Disease (Phase 1),"ABL Bio, Inc., Sanofi",alpha-synuclein,Immunotherapy (passive),,?fda_statuses[]=181&therapy_types[]=162 | ?therapy_types[]=162
saracatinib,Saracatinib,https://www.alzforum.org/therapeutics/saracatinib,AZD0530,"Alzheimer's Disease (Discontinued), Parkinson's Disease (Phase 1)",AstraZeneca,Other,Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
sargramostim,Sargramostim,https://www.alzforum.org/therapeutics/sargramostim,"GM-CSF Leukine , Leukine®","Alzheimer's Disease (Phase 2), Parkinson's Disease (Phase 1)","Genzyme, Partner Therapeutics, Inc., Sanofi","Inflammation, Other, Unknown",Other,Bone Marrow Stimulation,?fda_statuses[]=181&target_types[]=173 | ?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&target_types[]=175 | ?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&target_types[]=191 | ?fda_statuses[]=182&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=181&therapy_types[]=167 | ?fda_statuses[]=182&therapy_types[]=167 | ?therapy_types[]=167
sb-202026,SB 202026,https://www.alzforum.org/therapeutics/sb-202026,Memric,Alzheimer's Disease (Discontinued),,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
selnoflast,Selnoflast,https://www.alzforum.org/therapeutics/selnoflast,"RO7486967, RG-6418, IZD-334, somalix",Parkinson's Disease (Phase 1),"Hoffmann-La Roche, Inflazome Ltd.",Inflammation,Small Molecule,,?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
seltorexant,Seltorexant,https://www.alzforum.org/therapeutics/seltorexant,"JNJ-42847922, MIN-202",Alzheimer's Disease (Discontinued),Janssen,Other,Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
semagacestat,Semagacestat,https://www.alzforum.org/therapeutics/semagacestat,"LY450139 Dihydrate , hydroxylvaleryl monobenzocaprolactam",Alzheimer's Disease (Discontinued),Eli Lilly & Co.,Amyloid-Related,Small Molecule,None,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
semaglutide,Semaglutide,https://www.alzforum.org/therapeutics/semaglutide,"Ozempic, Wegovy, Rybelsus","Alzheimer's Disease (Phase 3), Parkinson's Disease (Phase 2)",Novo Nordisk A/S,Other,Other,"Type 2 Diabetes, Obesity, Protection against myocardial infarction and stroke",?fda_statuses[]=182&target_types[]=175 | ?fda_statuses[]=183&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=167 | ?fda_statuses[]=183&therapy_types[]=167 | ?therapy_types[]=167
sembragiline,Sembragiline,https://www.alzforum.org/therapeutics/sembragiline,"RO4602522, RG1577",Alzheimer's Disease (Discontinued),Evotech AG,"Other Neurotransmitters, Other",Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
semorinemab,Semorinemab,https://www.alzforum.org/therapeutics/semorinemab,"RO7105705 , MTAU9937A, RG6100",Alzheimer's Disease (Inactive),"AC Immune SA, Genentech, Hoffmann-La Roche",Tau,Immunotherapy (passive),,?fda_statuses[]=190&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=190&therapy_types[]=162 | ?therapy_types[]=162
sensory-stimulation-systems,Sensory Stimulation Systems,https://www.alzforum.org/therapeutics/sensory-stimulation-systems,"GENUS, Gamma entrainment using sensory stimuli, GammaSense Stimulation","Alzheimer's Disease (Phase 3), Parkinson's Disease (Not Regulated), Down's Syndrome (Not Regulated)","Cognito Therapeutics, Inc.","Amyloid-Related, Inflammation, Other","Combination, Procedural Intervention",,?fda_statuses[]=183&target_types[]=170 | ?fda_statuses[]=33161&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=183&target_types[]=173 | ?fda_statuses[]=33161&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=183&target_types[]=175 | ?fda_statuses[]=33161&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=183&therapy_types[]=36536 | ?fda_statuses[]=33161&therapy_types[]=36536 | ?therapy_types[]=36536 | ?fda_statuses[]=183&therapy_types[]=165 | ?fda_statuses[]=33161&therapy_types[]=165 | ?therapy_types[]=165
sgs-742,SGS-742,https://www.alzforum.org/therapeutics/sgs-742,"CGP-36742, DVD-742",Alzheimer's Disease (Discontinued),"Novartis Pharmaceuticals Corporation, Saegis Pharmaceuticals, Inc.",Other Neurotransmitters,Small Molecule,,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
shr-1707,SHR-1707,https://www.alzforum.org/therapeutics/shr-1707,,Alzheimer's Disease (Phase 2),,Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=182&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=182&therapy_types[]=162 | ?therapy_types[]=162
simufilam,Simufilam,https://www.alzforum.org/therapeutics/simufilam,"PTI-125, sumifilam",Alzheimer's Disease (Discontinued),Cassava Sciences,Amyloid-Related,Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
simvastatin,Simvastatin,https://www.alzforum.org/therapeutics/simvastatin,"Zocor®, Lipex®, Lipovas®, Denan®","Alzheimer's Disease (Inactive), Mild Cognitive Impairment (Phase 4)",Merck,Cholesterol,Small Molecule,Hypercholesterolemia and diabetic cardiomyopathy.,?fda_statuses[]=851&target_types[]=171 | ?fda_statuses[]=190&target_types[]=171 | ?target_types[]=171 | ?fda_statuses[]=851&therapy_types[]=166 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
snp318,SNP318,https://www.alzforum.org/therapeutics/snp318,,Alzheimer's Disease (Phase 1),SciNeuro Pharmaceuticals,Inflammation,Small Molecule,,?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
solanezumab,Solanezumab,https://www.alzforum.org/therapeutics/solanezumab,LY2062430,Alzheimer's Disease (Discontinued),Eli Lilly & Co.,Amyloid-Related,Immunotherapy (passive),None,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
solengepras,Solengepras,https://www.alzforum.org/therapeutics/solengepras,CVN424,Parkinson's Disease (Phase 3),Cerevance,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=183&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
souvenaid,Souvenaid,https://www.alzforum.org/therapeutics/souvenaid,Fortasyn Connect,Alzheimer's Disease (Not Regulated),Nutricia,Other,"Supplement, Dietary",,?fda_statuses[]=33161&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=33161&therapy_types[]=163 | ?therapy_types[]=163
spg302,SPG302,https://www.alzforum.org/therapeutics/spg302,,"Alzheimer's Disease (Phase 2), Amyotrophic Lateral Sclerosis (Phase 1/2)","Spinogenix, Inc.",Other Neurotransmitters,Small Molecule,,?fda_statuses[]=33251&target_types[]=176 | ?fda_statuses[]=182&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=33251&therapy_types[]=166 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
st101,ST101,https://www.alzforum.org/therapeutics/st101,ZSET1446,Alzheimer's Disease (Inactive),"Sonexa Therapeutics, Inc.",Unknown,Small Molecule,,?fda_statuses[]=190&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
suritozole,Suritozole,https://www.alzforum.org/therapeutics/suritozole,MD 26479,Alzheimer's Disease (Discontinued),"Aventis Pharmaceuticals, Inc. (was Hoechst)",Other Neurotransmitters,Small Molecule,,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
suvn-g3031,SUVN-G3031,https://www.alzforum.org/therapeutics/suvn-g3031,"Samelisant, 17v",Alzheimer's Disease (Phase 1),Suven Life Sciences Ltd,"Cholinergic System, Other Neurotransmitters",Small Molecule,,?fda_statuses[]=181&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=181&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
suvorexant,Suvorexant,https://www.alzforum.org/therapeutics/suvorexant,"Belsomra, MK-4305",Alzheimer's Disease (Approved),Merck,Other,Small Molecule,"Insomnia, Insomnia in mild to moderate Alzheimer's disease",?fda_statuses[]=184&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=184&therapy_types[]=166 | ?therapy_types[]=166
t3d-959,T3D-959,https://www.alzforum.org/therapeutics/t3d-959,DB959,Alzheimer's Disease (Phase 2),"T3D Therapeutics, Inc.",Other,Small Molecule,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
tacrine,Tacrine,https://www.alzforum.org/therapeutics/tacrine,Cognex™,Alzheimer's Disease (Approved),"Pfizer, Shionogi Pharma",Cholinergic System,Small Molecule,,?fda_statuses[]=184&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=184&therapy_types[]=166 | ?therapy_types[]=166
tak-341,TAK-341,https://www.alzforum.org/therapeutics/tak-341,MEDI1341,"Parkinson's Disease (Phase 1), Multiple System Atrophy (Phase 2)","AstraZeneca, Takeda Pharmaceutical Company",alpha-synuclein,Immunotherapy (passive),,?fda_statuses[]=181&therapy_types[]=162 | ?fda_statuses[]=182&therapy_types[]=162 | ?therapy_types[]=162
tavapadon,Tavapadon,https://www.alzforum.org/therapeutics/tavapadon,"PF-06649751, CVL-751",Parkinson's Disease (Phase 3),"AbbVie, Cerevel Therapeutics, LLC., Pfizer",Other Neurotransmitters,Small Molecule,,?fda_statuses[]=183&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
tb006,TB006,https://www.alzforum.org/therapeutics/tb006,,Alzheimer's Disease (Phase 1),"TrueBinding, Inc.",Inflammation,Immunotherapy (passive),,?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&therapy_types[]=162 | ?therapy_types[]=162
telmisartan,Telmisartan,https://www.alzforum.org/therapeutics/telmisartan,Micardis,Alzheimer's Disease (Phase 2),Boehringer Ingelheim,Other,Small Molecule,Hypertension,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
thalidomide,Thalidomide,https://www.alzforum.org/therapeutics/thalidomide,Thalomid®,Alzheimer's Disease (Discontinued),Celgene Corporation,"Amyloid-Related, Inflammation",Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
thn391,THN391,https://www.alzforum.org/therapeutics/thn391,,Alzheimer's Disease (Phase 1),"Therini Bio®, Inc.",Inflammation,Immunotherapy (passive),,?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&therapy_types[]=162 | ?therapy_types[]=162
tideglusib,Tideglusib,https://www.alzforum.org/therapeutics/tideglusib,"NP031112, Nypta® , Zentylor™ , Glycogen synthase kinase 3 inhibitor, NP12","Alzheimer's Disease (Discontinued), Progressive Supranuclear Palsy (Discontinued)",Zeltia Group,Tau,Small Molecule,,?fda_statuses[]=189&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
tilavonemab,Tilavonemab,https://www.alzforum.org/therapeutics/tilavonemab,"ABBV-8E12, C2N 8E12, HJ8.5","Progressive Supranuclear Palsy (Discontinued), Alzheimer's Disease (Discontinued)","AbbVie, C2N Diagnostics, LLC",Tau,Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
tpi-287,TPI 287,https://www.alzforum.org/therapeutics/tpi-287,,"Alzheimer's Disease (Inactive), Corticobasal Degeneration (Inactive), Progressive Supranuclear Palsy (Phase 1)",Cortice Biosciences,Tau,Small Molecule,,?fda_statuses[]=181&target_types[]=177 | ?fda_statuses[]=190&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=166 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
tpn-101,TPN-101,https://www.alzforum.org/therapeutics/tpn-101,"OBP-601, BMS-986001, censavudine, festinavir, 4'-ethynyl stavudine, 4'-ethynyl-d4T","ALS-FTD (Phase 2), Progressive Supranuclear Palsy (Phase 2)",Transposon Therapeutics,Inflammation,"Small Molecule, DNA/RNA-based",,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&therapy_types[]=164 | ?therapy_types[]=164 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
transcutaneous-auricular-vagal-afferent-nerve-stimulation,Transcutaneous auricular vagal afferent nerve stimulation,https://www.alzforum.org/therapeutics/transcutaneous-auricular-vagal-afferent-nerve-stimulation,"taVANS, tVANS","Alzheimer's Disease (Not Regulated), Mild Cognitive Impairment (Not Regulated), Parkinson's Disease (Not Regulated)",,Other Neurotransmitters,Other,,?fda_statuses[]=33161&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=33161&therapy_types[]=167 | ?therapy_types[]=167
trappsolr-cyclotm,Trappsol® Cyclo™,https://www.alzforum.org/therapeutics/trappsolr-cyclotm,"HP-beta-CD, HPbetaCD",Alzheimer's Disease (Phase 2),"Cyclo Therapeutics, Inc.",Cholesterol,Other,,?fda_statuses[]=182&target_types[]=171 | ?target_types[]=171 | ?fda_statuses[]=182&therapy_types[]=167 | ?therapy_types[]=167
trazodone,Trazodone,https://www.alzforum.org/therapeutics/trazodone,"Trazodone hydrochloride, Oleptro, Desyrel","Alzheimer's Disease (Phase 3), Mild Cognitive Impairment (Phase 3), Amyotrophic Lateral Sclerosis (Phase 2/3)",,Other Neurotransmitters,Small Molecule,Depression,?fda_statuses[]=931&target_types[]=176 | ?fda_statuses[]=183&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=931&therapy_types[]=166 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
tricaprilin,Tricaprilin,https://www.alzforum.org/therapeutics/tricaprilin,"AC-1204 , Caprylic triglyceride, AC-SD-03, CER-000, AC-OLE-O1-VA",Alzheimer's Disease (Phase 3),Cerecin Pte. Ltd.,Other,"Supplement, Dietary, Other",None,?fda_statuses[]=183&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=183&therapy_types[]=167 | ?therapy_types[]=167 | ?fda_statuses[]=183&therapy_types[]=163 | ?therapy_types[]=163
troculeucel,Troculeucel,https://www.alzforum.org/therapeutics/troculeucel,SNK01,Alzheimer's Disease (Phase 2),"NKGen Biotech, Inc.","Amyloid-Related, Inflammation",Other,,?fda_statuses[]=182&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&therapy_types[]=167 | ?therapy_types[]=167
trontinemab,Trontinemab,https://www.alzforum.org/therapeutics/trontinemab,"RO7126209, RG6102 , Brain shuttle gantenerumab",Alzheimer's Disease (Phase 3),Hoffmann-La Roche,Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=183&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=183&therapy_types[]=162 | ?therapy_types[]=162
troriluzole,Troriluzole,https://www.alzforum.org/therapeutics/troriluzole,"BHV-4157, trigriluzole, FC-4157",Alzheimer's Disease (Discontinued),Biohaven Pharmaceuticals,Other Neurotransmitters,Other,,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=167 | ?therapy_types[]=167
tw001,TW001,https://www.alzforum.org/therapeutics/tw001,"FNP122, FAB122, oral edaravone","Alzheimer's Disease (Phase 2), Amyotrophic Lateral Sclerosis (Phase 3)",Treeway B.V.,Other,Small Molecule,,?fda_statuses[]=182&target_types[]=175 | ?fda_statuses[]=183&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?fda_statuses[]=183&therapy_types[]=166 | ?therapy_types[]=166
ub-311,UB-311,https://www.alzforum.org/therapeutics/ub-311,,Alzheimer's Disease (Phase 2),"United Neuroscience, Vaxxinity",Amyloid-Related,Immunotherapy (active),,?fda_statuses[]=182&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=182&therapy_types[]=161 | ?therapy_types[]=161
ub-312,UB-312,https://www.alzforum.org/therapeutics/ub-312,,Parkinson's Disease (Phase 2),"United Neuroscience, Vaxxinity",alpha-synuclein,Immunotherapy (active),,?fda_statuses[]=182&therapy_types[]=161 | ?therapy_types[]=161
ucb0022,UCB0022,https://www.alzforum.org/therapeutics/ucb0022,,Parkinson's Disease (Phase 2),UCB S.A.,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=182&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
ucb7853,UCB7853,https://www.alzforum.org/therapeutics/ucb7853,,Parkinson's Disease (Phase 1),UCB S.A.,alpha-synuclein,Immunotherapy (passive),,?fda_statuses[]=181&therapy_types[]=162 | ?therapy_types[]=162
ulefnersen,Ulefnersen,https://www.alzforum.org/therapeutics/ulefnersen,"ION363, Jacifusen",Amyotrophic Lateral Sclerosis (Phase 3),IONIS Pharmaceuticals,Other,DNA/RNA-based,,?fda_statuses[]=183&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=183&therapy_types[]=164 | ?therapy_types[]=164
umibecestat,Umibecestat,https://www.alzforum.org/therapeutics/umibecestat,"CNP520, BACE Inhibitor",Alzheimer's Disease (Discontinued),"Amgen, Inc., Novartis Pharmaceuticals Corporation",Amyloid-Related,Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
vafidemstat,Vafidemstat,https://www.alzforum.org/therapeutics/vafidemstat,ORY-2001,Alzheimer's Disease (Phase 2),Oryzon Corporate,Other Neurotransmitters,Small Molecule,,?fda_statuses[]=182&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
valacyclovir,Valacyclovir,https://www.alzforum.org/therapeutics/valacyclovir,"Valtrex, Valaciclovir, 256U87",Alzheimer's Disease (Phase 2),GlaxoSmithKline (GSK),Other,Small Molecule,Herpes virus outbreaks,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
valproate,Valproate,https://www.alzforum.org/therapeutics/valproate,"Depakote, Depakene, Valproic acid , Divalproex sodium",Alzheimer's Disease (Inactive),Abbott Laboratories,Other Neurotransmitters,Small Molecule,"Epilepsy, Bipolar disorder, Migraine",?fda_statuses[]=190&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
vanutide-cridificar,Vanutide cridificar,https://www.alzforum.org/therapeutics/vanutide-cridificar,"ACC-001, PF-05236806",Alzheimer's Disease (Discontinued),Janssen,Amyloid-Related,Immunotherapy (active),None,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=161 | ?therapy_types[]=161
varenicline,Varenicline,https://www.alzforum.org/therapeutics/varenicline,"Champix™, Chantix™, Varenicline tartrate, CP-526,555, Alpha4 beta2 nicotinic receptor agonist",Alzheimer's Disease (Discontinued),Pfizer,Cholinergic System,Small Molecule,Smoking cessation,?fda_statuses[]=189&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
varoglutamstat,Varoglutamstat,https://www.alzforum.org/therapeutics/varoglutamstat,PQ912,Alzheimer's Disease (Discontinued),"Probiodrug AG, Vivoryon Therapeutics N.V.","Amyloid-Related, Inflammation",Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
vascepa,Vascepa,https://www.alzforum.org/therapeutics/vascepa,"Icosapent ethyl (IPE), Ethyl eicosapentaenoic acid (E-EPA), AMR101, Miraxion",Alzheimer's Disease (Phase 2/3),,Other,Small Molecule,"Severe hypertriglyceridemia, and to lower risk of cardiovascular events in people with elevated triglycerides",?fda_statuses[]=931&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=931&therapy_types[]=166 | ?therapy_types[]=166
venglustat,Venglustat,https://www.alzforum.org/therapeutics/venglustat,"Ibiglustat, GZ/SAR402671, Genz-682452",Parkinson's Disease (Inactive),"Genzyme, Sanofi","alpha-synuclein, Other",Small Molecule,,?fda_statuses[]=190&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=190&therapy_types[]=166 | ?therapy_types[]=166
verdiperstat,Verdiperstat,https://www.alzforum.org/therapeutics/verdiperstat,"AZD3241, BHV-3241","Motor Neuron Disease (Discontinued), Multiple System Atrophy (Discontinued), Primary Progressive Aphasia (Phase 1)","AstraZeneca, Biohaven Pharmaceuticals","Inflammation, Other",Small Molecule,,?fda_statuses[]=181&target_types[]=173 | ?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&target_types[]=175 | ?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
verubecestat,Verubecestat,https://www.alzforum.org/therapeutics/verubecestat,"MK-8931, MK-8931-009 , BACE inhibitor",Alzheimer's Disease (Discontinued),Merck,Amyloid-Related,Small Molecule,,?fda_statuses[]=189&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
vg-3927,VG-3927,https://www.alzforum.org/therapeutics/vg-3927,,Alzheimer's Disease (Phase 1),"Vigil Neuroscience, Inc.","Amyloid-Related, Inflammation",Small Molecule,,?fda_statuses[]=181&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
vgl101,VGL101,https://www.alzforum.org/therapeutics/vgl101,Iluzanebart,Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (Discontinued),"Vigil Neuroscience, Inc.","Inflammation, Other",Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
vhb937,VHB937,https://www.alzforum.org/therapeutics/vhb937,,"Alzheimer's Disease (Phase 1), Amyotrophic Lateral Sclerosis (Phase 2)",Novartis Pharmaceuticals Corporation,Amyloid-Related,Immunotherapy (passive),,?fda_statuses[]=181&target_types[]=170 | ?fda_statuses[]=182&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=181&therapy_types[]=162 | ?fda_statuses[]=182&therapy_types[]=162 | ?therapy_types[]=162
vodobatinib,Vodobatinib,https://www.alzforum.org/therapeutics/vodobatinib,"K0706, SCC-138, SCO-088","Parkinson's Disease (Discontinued), Dementia with Lewy Bodies (Discontinued)",Sun Pharma Advanced Research Company Ltd.,Other,Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
vq-101,VQ-101,https://www.alzforum.org/therapeutics/vq-101,,Parkinson's Disease (Phase 1),Vanqua Bio,"alpha-synuclein, Other",Small Molecule,,?fda_statuses[]=181&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=181&therapy_types[]=166 | ?therapy_types[]=166
vy-aadc,VY-AADC,https://www.alzforum.org/therapeutics/vy-aadc,"VY-AADC01, VY-AADC02",Parkinson's Disease (Discontinued),"Neurocrine Biosciences, Voyager Therapeutics",Other Neurotransmitters,DNA/RNA-based,,?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=164 | ?therapy_types[]=164
vy-tau01,VY-TAU01,https://www.alzforum.org/therapeutics/vy-tau01,"HC3LC2, Voyager_9, VY7523",Alzheimer's Disease (Phase 1),Voyager Therapeutics,Tau,Immunotherapy (passive),,?fda_statuses[]=181&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=181&therapy_types[]=162 | ?therapy_types[]=162
vyalev,Vyalev,https://www.alzforum.org/therapeutics/vyalev,"Produodopa, Foslevodopa/Foscarbidopa, ABBV-951, LDp/CDp",Parkinson's Disease (Approved),AbbVie,Other Neurotransmitters,Small Molecule,Motor fluctuations in advanced Parkinson’s disease,?fda_statuses[]=184&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=184&therapy_types[]=166 | ?therapy_types[]=166
wve-004,WVE-004,https://www.alzforum.org/therapeutics/wve-004,,"Frontotemporal Dementia (Discontinued), Amyotrophic Lateral Sclerosis (Discontinued)","Wave Life Sciences USA, Inc.",Other,DNA/RNA-based,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=164 | ?therapy_types[]=164
xaliproden,Xaliproden,https://www.alzforum.org/therapeutics/xaliproden,SR 57746A,Alzheimer's Disease (Discontinued),Sanofi,"Other Neurotransmitters, Other",Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&target_types[]=176 | ?target_types[]=176 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
xanamem,Xanamem,https://www.alzforum.org/therapeutics/xanamem,UE 2343,Alzheimer's Disease (Phase 2),Actinogen Medical,Other,Small Molecule,,?fda_statuses[]=182&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
xpro1595,XPro1595,https://www.alzforum.org/therapeutics/xpro1595,"Pegipanermin, INB03, NeuLiv, XENP1595, DN-TNF, XENP345, XPro™ , LIVNate","Alzheimer's Disease (Phase 2), Mild Cognitive Impairment (Phase 2)",INmune Bio Inc.,Inflammation,Other,,?fda_statuses[]=182&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=182&therapy_types[]=167 | ?therapy_types[]=167
young-plasma,Young Plasma,https://www.alzforum.org/therapeutics/young-plasma,,"Progressive Supranuclear Palsy (Inactive), Alzheimer's Disease (Inactive)","Alkahest, Inc., Grifols Biologicals Inc.","Inflammation, Other, Unknown",Other,,?fda_statuses[]=190&target_types[]=173 | ?target_types[]=173 | ?fda_statuses[]=190&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=190&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=190&therapy_types[]=167 | ?therapy_types[]=167
ytx-7739,YTX-7739,https://www.alzforum.org/therapeutics/ytx-7739,JNJ-0376,Parkinson's Disease (Discontinued),"Janssen, Yumanity Therapeutics",Other,Small Molecule,,?fda_statuses[]=189&target_types[]=175 | ?target_types[]=175 | ?fda_statuses[]=189&therapy_types[]=166 | ?therapy_types[]=166
zagotenemab,Zagotenemab,https://www.alzforum.org/therapeutics/zagotenemab,LY3303560,Alzheimer's Disease (Discontinued),Eli Lilly & Co.,"Tau, Unknown",Immunotherapy (passive),,?fda_statuses[]=189&target_types[]=177 | ?target_types[]=177 | ?fda_statuses[]=189&target_types[]=191 | ?target_types[]=191 | ?fda_statuses[]=189&therapy_types[]=162 | ?therapy_types[]=162
zervimesine,Zervimesine,https://www.alzforum.org/therapeutics/zervimesine,"CT1812 , Elayta","Alzheimer's Disease (Phase 2), Dementia with Lewy Bodies (Phase 2)",Cognition Therapeutics Inc.,Amyloid-Related,Small Molecule,,?fda_statuses[]=182&target_types[]=170 | ?target_types[]=170 | ?fda_statuses[]=182&therapy_types[]=166 | ?therapy_types[]=166
zunveyltm,ZunveylTM,https://www.alzforum.org/therapeutics/zunveyltm,"Benzgalantamine , ALPHA-1062, GLN-1062, Memogain",Alzheimer's Disease (Approved),"Alpha Cognition, Galantos Pharma",Cholinergic System,Small Molecule,,?fda_statuses[]=184&target_types[]=172 | ?target_types[]=172 | ?fda_statuses[]=184&therapy_types[]=166 | ?therapy_types[]=166
